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Abstract: Diabetes results from a defect in insulin production (type-1) or action (type-2) 
causing dysfunctional glucose uptake. Diabetic patients are predisposed to cardiac 
complications such as atrial fibrillation (AF). The heart is a major organ to utilize 
glucose; however, little is known about atrial glucose metabolism. Glucose transport into 
the cell via Glucose Transporters (GLUTs) is the rate-limiting step of glucose utilization. 
Although GLUT4 is the major cardiac isoform, GLUT8 has emerged as a novel isoform. 
Atrial structural remodeling and advanced glycation end products (AGEs) have been 
suggested as precursors to AF. However, glucose and insulin disturbances during 
diabetes may directly affect atrial function, potentially leading to AF. We hypothesize 
that the dysregulation of glucose metabolism in the diabetic atria underlies diabetes-
induced AF. The specific aims of this dissertation are to test the hypothesis that: 1) 
GLUT-4 and -8 translocation to the atrial cell surface is insulin regulated and is impaired 
during insulin-dependent diabetes; 2) GLUT-4 and -8 translocation will be impaired 
during insulin-resistance-induced AF; and 3) impaired glucose metabolism resulting from 
insulin dysregulation provides a metabolic substrate for the development of AF. GLUT 
protein expression was measured in atrial myocytes of healthy rats, in the atrial tissue of 
insulin-deficient (streptozotocin-induced) and insulin-resistant (high-fat-diet-induced) 
mice. Active cell surface GLUT content was measured using the biotinylated 
photolabeled assay in the perfused heart. AF was induced by transesophageal atrial 
pacing. Atrial fibrosis and AGE were measured using histological analysis.  We reported 
that both GLUT4 and GLUT8 are insulin sensitive in the healthy atria and are regulated 
by the insulin signaling pathway (i.e., Akt/AS160). Our data demonstrated that GLUT 
translocation is downregulated in the atria during insulin dysregulation. In addition, 
insulin treatment rescued GLUT translocation to the atrial cell surface during insulin 
deficiency but not during insulin resistance. We reported the absence of atrial fibrosis and 
AGE accumulation in animals with insulin dysregulation. Our results also indicated that 
insulin dysregulation significantly increases the vulnerability to AF. Overall, the results 
suggest that in the absence of atrial structural remodeling, insulin dysregulation may 
induce perturbations in energy production which could underlie the development of 
diabetes-induced AF.                                                             .  .                                                                                                              
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Diabetes mellitus is a serious metabolic disorder affecting 350 million people 
worldwide.
1
 Diabetes has now reached epidemic levels and has been identified as the 7th 
leading cause of death in the USA.
2;3
 Hyperglycemia, the hallmark of diabetes, results 
from an impaired glucose uptake due to either a lack of insulin production by pancreatic 
beta cells (type 1) or cellular insulin resistance (type 2). Diabetes can lead to multiple 
organ dysfunction including cardiomyopathy, coronary artery disease and atrial 
fibrillation (AF).
4
 Atrial fibrillation (AF), the most common sustained cardiac arrhythmia 
in the world, has been identified as an increasing public health problem as well.
5
 
Approximately 2% of the entire world population suffers from AF. In the United States 3 
million people are currently affected and it is predicted to increase to 8 million by 2050. 
It is also a 26 billion dollar economic burden in the US.
6
 AF highly increases the risk 
factors for heart failure, ischemic heart disease and stroke.
7-10
 
The development of AF is thought to be multifactorial, including structural and 
electrical remodeling.
11
 AF also increases energy demand, which is characterized by 





diabetes has recently been identified as a major and independent risk factor of AF.
13
 
Indeed, the risk factor of a diabetic patient to develop AF is 1.4-2.2 compared to a healthy 
non diabetic person.
14
 However, the underlying pathophysiologic mechanisms of AF are not 
well understood. In addition to structural-electrical remodeling, glucose and insulin 
disturbances may also directly affect the function of the atrium potentially leading to AF.
13
  
However, it is unknown whether a metabolic substrate underlies AF. In support of this novel 
concept, it has been shown that blood glucose level is significantly elevated during an AF 
attacks.
5;15;16
  It has also been reported that the risk of developing AF increases 
approximately 3% for each additional year of the duration of diabetes.
17
 Therefore, we 
hypothesize that diabetes modulates the progression of AF and that alterations in glucose 
metabolism during diabetes could be a major contributing factor to AF.
14;18;19
  
Since all cardiac myocytes contract for each heartbeat (with an estimated 1 billion 
heartbeats through the lifespan of most mammals), the energetic demands in the heart are 
extreme. In order to sustain this high energy demand, the rate of glucose utilization in the 
heart is greater than in skeletal muscle, adipose tissue and lung, despite the ability of the 
myocardium to use other substrates (i.e., fatty acids, lactate, ketone bodies and amino 
acids).
20
 During physiological condition, the heart generates ~30% of its total energy from 
glucose oxidation.
21
 Therefore, cardiac glucose uptake and utilization is crucial for proper 
cardiac function. This is germane to the fact that the atria, which contains the pacemaker of 
the heart, significantly contributes to the overall cardiac function. Although the rate of 
glucose utilization in the heart is greater than in other tissue, little is known about glucose 
metabolism in the atria during both healthy and disease states.
22
 Dysfunctional glucose 
3 
 
uptake in the cardiac tissue during diabetes could be one of the main underlying 
pathophysiological substrates that connects diabetes and atrial fibrillation. 
Glucose entry from the blood stream into cardiac myocytes is the rate-limiting step in 
glucose utilization and it is tightly regulated by a specialized family of membrane 
transporters known as glucose transporters (GLUT).
23
 GLUT4 has been identified as the 
major insulin sensitive cardiac isoform (~70% of total myocardium GLUTs).
24
 Although 
GLUT4 has been studied extensively in the striated muscle and adipose tissue, there is no 
study that reports the role and regulation of GLUT4 trafficking in the atria. Although GLUT4 
is the major isoform in the heart, in a study conducted by Katz et al., it has been reported that 
GLUT4 knockout mice do not develop hyperglycemia, suggesting that other GLUT isoforms 
could be involved in the regulation of whole-body glucose homeostasis.
25
 Recently, GLUT8 
has emerged as a novel isoform for glucose transport in striated muscle and adipose 
tissue.
23;26-30
 Although GLUT8 has been reported to be an insulin-dependent isoform in 
blastocysts,
31
 its functional role in the myocardium is yet to be determined. Although the 
downstream insulin signaling pathway has been studied in the ventricle, it is yet to be 
characterized in the atria. The majority of the studies that have investigated cardiac 
energetics have studied the global or left ventricular changes.
18;32-37
 Therefore, the role of 
glucose uptake and utilization in the atria has received little attention. Specifically, there  has 
been little to no studies that focus on glucose transport across the atria. 
Chronic hyperglycemia, the landmark of diabetes, accelerates the reaction between 
glucose and proteins that leads to the formation of advanced glycation end products (AGEs), 
which form irreversible cross-links throughout the lifetime of many large proteins (such as 
collagen and hemoglobin), covalently modifying their structure and function, starting at 8-12 
4 
 
weeks after the onset.
38-43
 During diabetes and to a lesser extent during aging, AGEs 
accumulate at an accelerated rate in various cell types and produce multiple organ 
dysfunctions.
39;44
 At organ level, AGEs structurally stiffen collagen backbones and further 
stimulate collagen deposition (by acting as agonists for AGE receptors), which ultimately 
leads to increased tissue fibrosis.
39;40;44-46
 In the heart, AGE accumulation contributes to 
diastolic dysfunction, by inducing myocardial fibrosis and stiffness.
40;45-49
 In addition, AGE 
activation by receptor binding to RAGE leads to the enhanced expression of pro-fibrotic 
markers and therefore can possibly contribute to myocardial fibrosis. However, its role in the 
development and progression of AF remains unclear. It has been reported that activation of 
AGE-RAGE axis leads to the cleavage of cell bound RAGEs and produce soluble RAGE 
(sRAGE). Increased plasma levels AGE and sRAGE have been reported in patients with 
AF.
50;51
 However, whether AGEs accumulation during diabetes is the cause or simply 
correlate with the incidence of AF needs to be further investigated.    
The major goal of this study is to identify a novel metabolic substrate that underlies 
the pathophysiology of diabetes-induced atrial fibrillation. In order to achieve this goal, we 
will use healthy, type 1 and type 2 diabetic rodent models to characterize the role and 
regulation of insulin sensitive GLUTs during diabetes and diabetes-induced atrial fibrillation. 
In addition, we will investigate the mechanisms by which diabetes could induce possible 
metabolic and structural changes that render the diabetic atria vulnerable to atrial fibrillation. 
Insights gained from this study could lead to the identification of novel metabolic therapeutic 
targets for patients affected by diabetes and/or AF.  
Central Hypothesis:  Impaired glucose metabolism during diabetes will provide a metabolic 
arrhythmogenic substrate which underlies the development and maintenance of AF. 
5 
 
Specific Aim 1: To test the hypothesis that GLUT-4 and -8 translocation to the atrial cell surface 
will be regulated by insulin and impaired during insulin-dependent diabetes. 
Specific Aim 2: To test the hypothesis that GLUT-4 and -8 translocation to the atrial cell 
surface will be impaired during insulin-resistance-induced AF. 
Specific Aim 3: To test the hypothesis that impaired glucose metabolism resulting from 
insulin dysregulation provides a metabolic substrate for the development and maintenance of 






REVIEW OF LITERATURE 
 
2.1. Diabetes 
Diabetes mellitus affects almost 18.1 million people in the United States and 
accounts for 225,000 deaths per year.
2
 According to The Centers for Disease Control and 
Prevention, 40 million people have been diagnosed with pre-diabetes with 2 to 4 million 
new cases occurring every year.
52
 A diabetic condition is defined as the presence of an 
elevated plasma glucose concentration known as hyperglycemia.
53
 In a healthy 
vasculature, during fasting conditions, the plasma glucose concentration is 80-140 
mg/dL. In humans, a diabetic condition is diagnosed either if the fasting glucose level 
exceeds 140 mg/dL or if the glucose level is higher than 200 mg/dL two hours after the 
intake of 75g of oral glucose.
4
 To understand the pathogenesis of diabetes it is important 
to understand the mechanisms for glucose homeostasis in the normal vasculature during 
the absorptive and the post-absorptive state.
2
 During the absorptive state (after a meal), 
the ingested nutrients enter the blood from the gastrointestinal tract, whereas during the 
post-absorptive state (such as 10-12 hours overnight fast) the gastrointestinal tract is  
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empty and energy must be supplied from the glucose stores of the body, such as 
the liver and kidney.
54
 These two organs are responsible for the production of 
endogenous glucose during the post-absorptive state. The rate of use of basal glucose 
(2.0mg/kg/min) in the body is exactly matched by the endogenous glucose production by 
the liver (85%) and the kidney (15%), and therefore maintains glucose homeostasis.
4
  
 During the absorptive state, the plasma glucose concentration gradually increases, 
the beta cells in the islets of Langerhans in the pancreas are sensitive to this alteration in 
glucose concentration and produce the hormone insulin.
54
 The presence of insulin inhibits 
endogenous glucose production and facilitates the uptake of glucose into insulin sensitive 
tissues, such as striated muscle tissue (80-85% of the total glucose uptake), the liver and 
adipose tissue (where the glucose is stored as glycogen and triglycerides to be used 
during the post-absorptive state).
4
 When tissues absorb glucose from the blood stream, 
the plasma glucose concentration decreases, causing a down-regulation in insulin 
production. It is important to note that the increase in plasma concentration of insulin is 
one of the major causes of all absorptive state events, and the decreased plasma 
concentration of insulin is the major cause of all post-absorptive state events.
4
 However, 
in diabetes pathogenesis, insulin is either insufficient in quantity or functionally unable to 
facilitate the glucose transport into the tissue. Thus, based on the exact condition and the 
amount of insulin present in the blood, diabetes can be classified into two groups: insulin-
dependent diabetes mellitus or type 1 diabetes and non-insulin dependent diabetes 
mellitus or type 2 diabetes. In type 1 diabetes, the islets of Langerhans do not produce 
sufficient insulin and thus insulin is largely absent in the plasma. In type 2 diabetes, 
insulin is present at near normal or above normal level in the plasma (caused by the 
8 
 
diseased state), but becomes ineffective in the normally insulin sensitive tissues due to 
constant exposure, resulting in insulin resistance. 
54
  
 2.1.1 Type I Diabetes 
Type 1 diabetes (T1Dx) is characterized by the body’s inability to produce insulin 
due to immunological disruption of pancreatic beta cells.
55-58
 Apart from sudden 
hyperglycemia, rising HbA1c levels and an impaired fasting glucose tolerance are also 
hallmarks of type-1 diabetes. During this disease the plasma blood glucose level rises 
above 300mg/dL and the subjects are severely dependent on external insulin for 
survival.
59
 T1Dx constitutes of 5-10% of the total diabetic population.
60;61
 In the United 
States approximately 1.25 million people are suffering from T1Dx, and approximately 
40,000 new patients are diagnosed  every year.  This disease has also been associated 
with an estimated loss of life expectancy of 13 years.
60-62
  
T1Dx is also known as juvenile diabetes as it is mostly diagnosed during 
childhood or early adulthood with a sudden and severe presentation.
62-64
 50-60% of those 
diagnosed with T1Dx are younger than 16-18 years and this disease occurs at low 
incidence during early adulthood (20-25 years).
63
 Early symptoms of T1Dx include 
polyuria (excessive urination), polydipsia (increased thirst), xerostomia (dry mouth), 
polyphagia (increased hunger), fatigue, and weight loss.
65
 
T1Dx is thought to be caused by a combination of genetic susceptibility and 
triggering environmental agents. Although there is yet to be determined a gene that is 
either necessary or sufficient to predict the development of T1Dx, the Human Leukocyte 
Antigen (HLA) complex has been identified to have the greatest contribution 
9 
 
(approximately 60%) to the disease. Among the three classes of the HLA gene, class II 
has been reported to have the strongest association with T1Dx. These genes take part in 
the immune response by participating in the presentation of beta cells’ antigen peptides 
(either by promoting anti-self-reactivity or by the failure to regulate immune response).
66-
69
 Despite two decades of intensive research, the environmental factors that induce the 
pathogenesis of T1Dx are still debated. Some of the proposed factors include viral 
infection, early infant diet (breast feeding vs. early introduction to cow’s milk 




  T1Dx is characterized by hyperglycemia (>350mg/dL) due to the lack of insulin 
production caused by the immune-mediated destruction of the pancreatic beta cells.
76;77
 
At the time of clinical diagnosis of T1Dx approximately 80% of the beta cell is 
destroyed, and the islet is affected by insulitis (infiltration of chronic inflammatory T 
cells, B cells and macrophages).
78;79
 The first signs of T1Dx are the presentation of islets 
auto antibodies and their antigens which are reactive to the islet cells such as glutamic 
acid decarboxylase (GADAs), insulin (IAA), and tyrosine phosphatase (IA2As).
80
 These 
autoantibodies are the earliest markers towards the autoimmunity of beta cells and 
precursor to beta cell destruction. Beta cell destruction (i.e. loss of beta cell mass) has 
been non-linearly correlated with the development of islet autoantibodies.
81
 It is also 
believed that beta cell destruction during T1Dx is T-cell mediated.
58
 It is thought that the 
beta cells themselves produce the beta cell antigens due to cellular turnover or damage. 
These antigens are processed and presented to the helper T cells by antigen presenting 
cells, namely macrophages and dendritic cells. The helper T cells recognize the beta cell 
10 
 
antigen peptides by the MHC (major histocompatibility complex) molecules on the 
macrophages and dendritic cells that have infiltrated the islet and become activated. Once 
activated the T cells penetrate the islets and differentiate into cytotoxic T cells. These 
activated T cells also release pro-inflammatory cytokines such as TNF-α (tumor necrosis 
factor-α), IL-1β (interleukin-1β), IFN-γ (interferon- γ) and soluble free radicals O2, NO, 
and H2O2.
57;76;82-89
 These cytokines act in synergy during the inflammation of pancreatic 
beta cells and eventually lead to the activation of NF-κB followed by the destruction of 
the pancreatic beta cells, which are highly susceptible to cytokine mediated killing.
76
 The 
increases in soluble free radicals also increase the oxidative stress and add to the beta cell 
damage.
90-93
 In this manner, macrophages, T cells, cytokines, and oxidative stress 
synergistically act on beta cell destruction leading to the development of autoimmune 
T1Dx. Once beta cell destruction has begun its progression, it can be quite variable 
depending on the subject’s age, body mass index physical activity levels, etc.
94
  
Long term T1Dx has been associated with both micro- and macro-vascular 
complications.
95
 Some of the most common microvascular complications include diabetic 
nephropathy, microalbuminuria and diabetic retinopathy.
96-98
 In the context of 
macrovascular disease, it has been reported that T1Dx can increase the relative risk factor 
for cardiovascular diseases such as hypertension, peripheral vascular disease, coronary 
artery disease and atherosclerosis compared to non-diabetic patients.
99-102
 T1Dx has also 
been associated with reduced vascular repair, impaired endothelium dependent 
vasodilation, impaired wound healing, endothelial dysfunction, and reduction in collateral 
vessel formation during ischemia.
103-108
 Cardiac dysfunction such as impairment in left 





 So far it has been suggested that hyperglycemia and increased reactive 




2.1.2 Type II Diabetes  
In type 2 diabetes mellitus (T2Dx), as the fasting plasma glucose rises from 80 to 
140 mg/dL, the fasting plasma insulin concentration rises progressively, reaching a peak 
that is 2-2.5 times the comparative levels found in non-diabetic controls.
4
 However, even 
this rise in plasma insulin cannot offset the deterioration in glucose homeostasis, and the 
plasma glucose concentration continues to rise. As the fasting plasma glucose 
concentration exceeds 160 mg/dL, the pancreatic beta cells become unable to maintain 
the elevated rate of insulin secretion and the insulin concentration starts to decline.
113
 As 
the insulin concentration begins to decrease, the liver senses this change in concentration 
and begins the production of endogenous glucose, resulting in an overall increase in the 
plasma glucose concentration.
113
 Finally, as the fasting glucose concentration exceeds 
200-220 mg/dL, the plasma insulin response to the glucose is markedly diminished 
resulting in a prolonged hyperglycemic condition.
114
 
 It has been well documented that  patients with T2Dx cannot elicit a normal 
glucose metabolic response even with maximum stimulation of plasma insulin 
concentration.
2
 This may be due to insulin resistance in the insulin sensitive tissues, loss 
of glucose sensitivity, reduction in mass or enhanced apoptosis of the pancreatic beta 
cells.
114
 The number of beta cells in the pancreas is an important determinant of the total 
amount of insulin secreted. Several studies have reported a significant reduction in beta 
12 
 
cell mass (20-50%) and an approximate three-fold increase in beta cell apoptosis.
115
 It 
seems likely that the loss of beta cell mass and functionality could contribute to the 
impairment of insulin secretion during T2Dx. It has been documented that, during the 
disease conditions, the of insulin sensitivity cause the liver to continue the production of 
glucose, even in the presence of insulin in the absorptive state.
4
 As a result, two factors 
simultaneously contribute to the increase in plasma glucose concentration: 1) ingested 
glucose and 2) the endogenously produced glucose, causing the prolonged hyperglycemia 
in T2Dx.  
The sustained hyperglycemia, caused by the ineffectiveness or the lack of 
sufficient insulin, induces other disease conditions and dysfunctions in the vasculature, 
such as intracellular accumulation of certain glucose metabolites (such as advance 
glycation end products), endothelial and mitochondrial dysfunction, increase an in 
oxidative stress and the possibility of glucose cross-link formation with proteins (for 
more details see 2.3.3).
38;116
 As albumin is the most abundant plasma protein with a low 
turnover rate, it is very susceptible to such cross-link formation and protein 
glycosylations. As a result, patients with T2Dx become more susceptible to 
atherosclerosis, kidney failure, small vessel and nerve disease, infection and blindness. 
2.1.3 Cardiac Complications Associated with Diabetes Mellitus 
Diabetes Mellitus significantly increases the risk factors for cardiac complication 
and cardiovascular disease (CVDs). The American Heart Association identified diabetes 
as one of the 7 major risk factors for CVDs. It has been reported that risk of mortality 
with some form of cardiac disease is 2-4 times higher in a diabetic patient compared to a 
13 
 
non-diabetic person. The diabetic vasculature differs vastly from the normal vasculature 
but interestingly, resembles the pathologies of many CVDs.
117
 The mechanisms for this 
are only partially understood. However, few of the major risk factors relating both of the 
disease conditions include hypertension, high cholesterol, obesity, high blood sugar, and 
smoking.
38
 Some of the most common cardiac complications associated with diabetes are 




2.2 Atrial Fibrillation 
 Atrial fibrillation is the most common and sustained cardiac arrhythmia in the 
world. Approximately 2% of the entire world population suffers from atrial fibrillation 
(AF). It is predicted that, the affected population will reach 16 million in the United 
States by the year 2016.
118
 The onset of atrial fibrillation has been attributed to 
disorganized and irregular electrical impulses originating in the left atria, thus initiating 
electrical impulses from the left atria to the right (reverse of the physiological signal path) 
and causing initiation and perpetuation of reentry circuits in the right atria. These 
multiple circuits eventually induce chaotic rhythm in the atria, known as AF.
119;120
  
Atrial fibrillation is characterized by 3 stages: paroxysmal, persistent, and 
permanent. The paroxysmal state of AF is a silent state; it is self-terminated within 48 
hours and is non-symptomatic. Approximately 15% of patients with paroxysmal AF are 
predicted to progress to a more persistent state, where AF sustains for at least 7 days and 
requires cardioversion. In most cases, this eventually leads to a more permanent state of 
AF where sinus rhythm is completely absent.
118
  Permanent AF is a condition in which 
14 
 
sinus rhythm cannot be restored with treatment.
121
 The mechanisms involved in the 
progression of paroxysmal-AF to the more persistent states are highly variable among 
individual subjects and are not well understood. It has been reported that chronic atrial 
pacing in dogs and goats results in the development of sustained AF.
122
 
There has been ongoing research during the last 50 years to understand the 
underlying mechanisms that promote AF.
123-126
 There have been three proposed models: 
1) ectopic foci 2) single circuit reentry and 3) multiple circuit reentry.
127-131
 In the past 
two decades, scientists have come to a consensus that AF is the result of a combination of 
all the three models. The ectopic foci (possibly located near the pulmonary veins of the 
left atrium)
127
 can initiate or drive AF by rapid firing.
128
 This rapid firing of the ectopic 
foci (which is at a regular rhythm faster or slower than firing of the SA node) can cause 
fibrillary activity as it disrupts the conduction of the wave generated at the sinoatrial node 
(SA node) of the right atrium.
130
 However, if the ectopic firing rate is slower than the SA 
node firing rate, no fibrillatory activity can occur.
130;131
 The ectopic foci can also act as a 
substrate where reentrant circuits can occur.
132
 In single circuit reentry model, only one 
circuit which is continuously firing (against the SA node activity) causes irregular 
fractionated atrial response which leads to fibrillation of the atrium.
123
 The multiple 
circuit model is similar to the previous model, with the exception of the existence of 
multiple reentry circuits.
122;129
 These circuits cycle through the atria simultaneously and 
interact with each other, disrupting the atrial conduction system and promote an 
arrhythmogenic state.
127
 Although there is debate in the literature, the current consensus 
is that, the initial state of paroxysmal AF results from the formation of ectopic foci and 
single reentry circuits.
130
 As the disease progresses, due to atrial structural and electrical 
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remodeling (caused by the tachycardia) there is the introduction of multiple circuits 
which lead to the permanent forms of AF.
122;130;131
  
Factors that influence and cause the reentry of the circuits include wavelength of 
the generated impulse, conduction velocity, circuit length, action potential duration and 
refractory period (the period in which the cardiac myocyte remains inexcitable).
122;129-131
 
It has been reported that during AF there is decrease in action potential duration and 
shortening of the refractory period and wavelength as well as an overall decrease in 
conduction velocity (due to electrical and structural remodeling of the atrial tissue.)
130;131
  
Wavelength is defined as the distance traveled by a single impulse during a single 
refractory period (wavelength= refractory period x conduction velocity).
130;131
 The 
reentry circuit is the smallest circuit that can maintain continuous activity and reactivate 
the excitable core substrate of the atrial tissue by initiating continuous centripetal 
impulses.
124;125
 Wavelengths determine the shortest path length for the reentry 
circuits.
130;131
  Therefore, factors that reduce the size of atrial wavelengths also decrease 
the dimension of reentry currents, which in turn increases the potential number of 
simultaneous circuits.
122;130;131
  In order to form the reentry circuits, the conduction time 
of a single wavelength (i.e. circuit time) must be greater than the refractory period.  If the 
conduction velocity is low (i.e. increase in conduction time) then it becomes more likely 
that all the potential excitable points in the atrium have had the time to recover from 
excitation and are able to be reactivated by the invading reentry impulses.
122;127;133
 
Therefore, the shorter the refractory period, the higher the probability of reactivation by 
the reentry impulses. It is suggested that refractory period is the sole determinant of 
circuit time and the rate of tachycardia during AF. Wijffels et al. reported that during the 
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development of chronic atrial fibrillation, a progressive shortening of the refractory 
period was observed with the decrease in fibrillation interval. The shortening of the 
refractory period to a critical value was required to stabilize AF during atrial pacing in 
their goat model. In the same study it was also reported that both the wavelength 
dimension and conduction time was reduced as AF became more stable.
122
 
The decrease in action potential duration (APD) of atrial myocytes has been 
strongly associated with the pathology of AF. Action potential duration is determined 
mainly by the duration of phase 2 (inward Ca
2+
 current, keeping the myocyte depolarized 
and outward K
+   
 rectifier current, tend to repolarize the myocyte) or the plateau phase. It 
has been reported that during AF shortening of the APD occurs as there is a reduction in 
inward Ca
2+
 current and enhancement in the outward K
+
 current, resulting in a shorter 
plateau period. Faster repolarizations in the cardiac myocyte make it more 




Although the mechanisms behind the shortening of the refractory period still 
remains unclear,  a few of the possible causes are changes in the autonomic nervous 
system, ischemia, and the high rate of electrical activation. The role of the autonomic 
nervous system has often been associated with AF. Coumel et al. reported that initiation 
of AF was associated with high vagal tone and adrenergic stimulation of the heart.
137;138
 
Studies have reported that adenosine and acetylcholine are pro-fibrillatory as they shorten 




 without having an effect on the 





 The high rate of electrical activity during the initial stages of 
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AF can cause tachycardia modulated atrial remodeling that affects the synthesis and 




Inflammation and atrial dilation also make the atrium more susceptible to AF. The 
number of wavelets that can coexist simultaneously is dependent on the mass and surface 
area of the atrial tissue.
122;139;143
 Atrial dilation increases the total surface area atria of the 
atrial tissue which can now accommodate higher number of reentry circuits. On the other 
hand the wavelengths of the impulses are not directly proportional to the size of the 
atria.
139
 Since the wavelengths are considerably shortened during AF and circuit length is 
directly proportional to wavelength, dilated atria can thus allow a higher number of 
reentry circuits simultaneously and make the atrium susceptible to AF.
144
 Hearts of larger 
size (those of large animal models and humans) are therefore more susceptible to AF.  
2.2.1 Atrial Remodeling  
As, “Atrial fibrillation begets atrial fibrillation”,
122
 AF itself induces electrical, 
contractile and molecular remodeling in the atrial myocytes that further propagate the 
disease pathology. This remodeling can occur within minutes and is thought to be the 
transitory mechanism behind the development of persistent AF from paroxysmal AF. 
Clinical trials and various animal models have identified two components of atrial 
remodeling: 1) remodeling due to rapid tachy-arrhythmia (atrial flutter and paroxysmal 
AF); 2) Atrial structural remodeling. It has been suggested that electrical remodeling 
occurs first, followed by a decrease in atrial contractility and finally structural remodeling 





 Tachycardia has been shown to induce rapid atrial activation in the paroxysmal 
stages of AF, in turn inducing electrical remodeling in atrial tissue.
130
  At the onset of AF 
the atrial rate increases approximately 8 fold (SR 60/min vs AF 340-350/min in humans). 
To accommodate this higher rate there is an increase in Ca
2+
 load in the myocytes. Since 
Ca
2+
 is cytotoxic, the myocytes respond by reducing Ca
2+
 influx via the L-type Ca
2+
 
current. However, this results in decreased APD (and in turn the refractory period) and 
wavelength which favors the perpetuation of AF (since smaller wavelength allows more 
atrial reentry circuits).
130;135;146
 As AF becomes more sustained it has been reported that 
there is persistent decrease in the L-type Ca
2+
 current via not only the inactivation but 
also the downregulation of mRNA expression  (50-60%) of subunits that form the L-type 
Ca
2+
 channels. However the detailed mechanism of the molecular basis of abnormal Ca
2+
 
handling is still not well understood.
147
 Although the expressions of ryanodine receptors 
and phospholamban activity unaltered during AF, there is a suggested upregulation of 
NCX (Na/Ca ion exchanger).
147;148
 Increase in NCX activity could increase the inward 
Na+ current and increase the propensity of delayed after depolarization (DADs) and 
contribute towards the pathogenesis of AF.
130;131;135
 
Abbreviation of APD and shortening the refractory period during AF has also 
been attributed to the increased inward-rectifier K
+
 current. Increased vagal tone 
association with the autonomic alterations during AF results in the release of 
acetylcholine, which in turn activates the acetylcholine activated K
+ 
(IK,Ach). Atienza et al. 
reported that activation of IK,Ach  by infusing adenosine increased reentry frequency in 
human patients of both paroxysmal and persistent AF. The increase of IK,Ach causes 
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shortening of the APD and cell membrane hyperpolarization of the atrial myocytes, and 
enhances the susceptibility of AF.
149;150
 
In addition to the shortening of the refractory period, atrial tachycardia slows 
down intra-atrial conduction. It has been reported that conduction velocity is decreased 
during deletion of connexins (gap junction components).
151;152
 Although there has been 
debate regarding the role of gap junction activity in the pathogenesis of AF. Verheule et 
at. reported decreased conduction velocity (by 30%) and AF inducibility in Connexin 40 
knockout mice.
153
 In a different study, Hagendorff et al. reported that during atrial pacing 
there were conduction disturbances in sinoatrial, intra-atrial and atrioventricular 
conduction in Connexin 40 deficient mice.
154
 Kostin et al. reported a decrease in 
expression of Connexin 40 and 43 in the right atrial appendages (RAA) in human patients 
with AF. This study also reported a lateralization of the connexins in the AF patients, 
deviating from their physiological location at the junctions of the intercalated 
discs.
155
Together the combination of heterogeneity within the conduction pathway and 
decreased wavelength promotes multiple circuit reentry and increases the propensity of 
AF.   
  Atrial structural remodeling, particularly interstitial fibrosis has been identified as 
one of the important contributors to the AF substrate.
130
 It has been reported that atrial 
fibrosis and AF occur in a concurrent manner, however whether or not there exists a 
direct cause and effect relationship remains elusive.
156
 Atrial fibrosis is hard to reverse 
and therefore has been considered as major contributor in the progression from 
paroxysmal to persistent and permanent AF.
157
 Myocardial fibrosis occurs due to an 
imbalance between the extracellular matrix (ECM) proteins that results in the 
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proliferation of fibroblast and excessive ECM protein build up in the interstitial space 
between the two adjacent myocytes. The increased space between the cardiac myocytes 
due to the fibrotic deposit and expansion of ECM can cause conduction delays and allow 
alternate pathways of conduction, thereby increasing the propensity of AF.
156;158
 
Interestingly, it has been reported that the atrium is more vulnerable to fibrosis compared 
to the ventricle.
159
 Frustaci et al. reported the existence of patchy fibrosis in 
endomyocardial biopsies from the right atrium of human patients with paroxysmal lone 
AF (AF in the absence of other cardiac complications).
160;161
 
Transforming growth factor 1 (TGFβ-1), secreted by both myocytes and 
fibroblasts, is one of the well-established pro-fibrotic molecules. It has been suggested 
that cardiac overexpression of active TGFβ-1 causes atrial fibrosis, disruption in atrial 
conductivity, and promotes AF.
162;163
 Nakijima et al. reported that overexpression of 
TGFβ-1 in the atria was sufficient to induced atrial fibrosis in transgenic mice. Venteclef 
et al. reported increased expression of TGFβ-1 in rat atrial myocyte expressing higher 
interstitial fibrosis in vitro.
164
 Verheule et al. reported that selective overexpression of 
TGFβ-1 in the atrium was sufficient to increase AF inducibility during rapid atrial pacing 
in a transgenic mice model.
162
 However, these mice did not develop AF spontaneously. In 
a large animal model, Polejaeva et al. reported that overexpression of TGFβ-1 in the heart 
resulted in atrial fibrosis which in turn increased inducibility of AF in transgenic goats.
165
 
Chen et al. reported enhanced expression of TGFβ-1 in the porcine atrial tissue that was 
induced to rapid atrial pacing.
166
  Together, the reports indicate that atrial fibrosis is a 
common factor in animal models of AF and in human patients with AF.  
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TGFβ-1 acts through the SMAD pathway to stimulate fibroblast activation and 
collagen deposition.
167
  The presence of TGFβ-1 dramatically increases fibroblast 
function upregulating ECM protein synthesis (collagen production) without offsetting the 
collagen degradation.
168
 Ventclef et al. reported fibrotic deposits in the atrial biopsies 
from AF patients mostly consisted of collagen I, III and VI.
164
 In a similar study, 
Mukherjee et al. reported increased collagen deposits in the atrium of patients with AF.
169
 
Collagen fibers represent electrical barriers and therefore cause dysregulation of atrial 
impulse transduction and in turn facilitate the formation of reentry circuits.
170
 
The regulatory mechanisms that underlie extracellular matrix (ECM) remodeling 
are not well understood. An important contributing factor to ECM remodeling in the 
myocardium is matrix metalloproteinases (MMPs). MMPs are a family of proteolytic 
enzymes involved in the metabolism of ECM proteins (such as collagen) and can cause 
tissue remodeling.
171
 Endogenous tissue inhibitors of MMPs (TIMPs) moderate the 
activity of MMPs and maintain balance between ECM protein turnover rates.  The 
myocardial ECM is a dynamic structure that plays a crucial role in providing structural 
supporting network during cardiac cycle and is critical for the maintenance of overall 
structural integrity of the cardiac chambers.
169;171
 Therefore, alteration and disruption in 
the ECM integrity results in loss of structural support, continuity and impairment in 
signal transduction. MMPs, responsible for the degradation of ECM proteins, are 
expressed at a very low level in the healthy myocardium. However substantial 
upregulation of MMPs have been associated with heart failure and AF.
171
  It has been 
reported that activation of MMPs and downregulation of TIMPs results in the 
enhancement of atrial fibrosis.
169;171
 In a study conducted by Moe et al., it was reported 
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that inhibition of MMPs cause a reduction in atrial fibrosis and subsequent decrease in 
AF inducibility in a canine model.
172
 These findings lead to the identification of MMPs 
as a potential target for atrial fibrosis and AF. 
 Cardiac myocytes predominantly synthesize and release MMP2 and MMP9, 
among which upregulation of MMP9 has been identified as an individual risk factor for 
AF.
166
 In a study designed to investigate the role of MMPs during AF, Chen et al. 
reported that during rapid atrial pacing in a porcine model, there was an increased 
expression of MMP9 in its pro (active) form. This study demonstrated increased 
gelatinase activity in ECM due to increased MMP9. They also reported increased TIMP-
1 co-localization with MMP9 in addition to enhanced expression of glycosylated TIMP-1 
in the atrial tissue. This study hypothesized that TIMP-1 was present to subsidize and 
inhibit the upregulated activity of MMP9.
166
 In a similar study Hoit et al. reported that 
rapid atrial pacing in a canine model increased MMP9 activity in the atrium.
173
 Nakano et 
al. also reported significant increase in MMP9 levels in atrial biopsies of human patients 
with both paroxysmal and persistent AF.
145
 And reported that the level of MMP9 
increased step by step with the severity of the disease (from paroxysmal to persistent 
AF). Interestingly, none of these studies report alteration in MMP2 expression, indicating 
that MMP9 is mostly associated with atrial remodeling during spontaneous and/or 
induced AF. In another study by Meiner et al., it was reported that reduced myocardial 
fibrosis was associated with decreased activity of MMP9.
174
  It has been postulated that 
MMP9 can modulate the activation of TGFβ-1 and thereby participate in atrial fibrosis. In 
a case-cohort based study Huxley et al. reported that increased MMP9 was associated 
with increase in risk factor for AF.
175
 Therefore, collectively, the results from these 
23 
 
studies indicate that MMP9 significantly contribute towards atrial remodeling and render 
the atria susceptible to AF. 
One of the predominant changes in the atria at the onset of AF is glycogen 
accumulation.
176-180
 It has been reported that within 4 weeks after the onset of AF there is 
a marked increase in the glycogen accumulation in the atria, which was hypothesized to 
be responsible for the perpetuation of persistent AF at the end of 8 weeks. 
177;181
 Based on 
this hypothesis, Embi, et al. investigated the location and distribution of glycogen in the 
left and right atrial appendages in the healthy goat heart, and reported that the left atrial 
appendage (LAA) has a significant higher concentration of glycogen and it is located 
against the intercalated disc and at the myocyte junction, whereas in the right atrial 
appendage (RAA) the glycogen granules where scattered within the mycoytes.
179
 This 
study also suggested that this regional difference in the glycogen accumulation between 
the LAA and the RAA could be the major contributing factor to the initiation of the 
arrhythmia in the LAA. The importance of the location of the glycogen molecules are of 
particular significance in the electrical signal transduction pathway, as the gap junction 
pores can only allow molecules of a given size to pass from cell to cell and given that the 
glycogen molecules are of higher molecular size create an obstacle in the path.
182
 
Furthermore, rapid atrial pacing causes remodeling of the gap junctional proteins 
(connexin 40) causing disturbance in the conduction pathway.
183
 Therefore it has been 
suggested that locational increase in the glycogen molecule may cause fractionated 
intracellular communication, causing a disruption in atrial syncytium.
179
 It is also 
reported that the LAA have lower conduction speed and higher resistance compared to 





increase in glycogen accumulation is suggested to be a major pathophysiological factor in 
the propensity of sustained/ permanent AF.
179;180
 
In the follow up study of Embi et al., Zhang et al. reported significant increase in 
glycogen accumulation in the LAA against the intercalated discs extending into the 
myocyte and potentially creating a longitudinal and lateral conduction blockade between 
side by side myocytes after AF was induced in canine hearts.
180
 There was significant 
increase in glycogen accumulation in the atria within 48 hours of rapid atrial pacing 
which eventually led to permanent AF.
180
  There was also significant increase of 
glycogen in the right atria; although they were scattered molecules within the myocytes. 
However, there was significant increase in glycogen concentration in both atria 8 weeks 
after the induction of AF compared to baseline.
180
 This study also reported significant 
increase in atrial fibrosis and an increase in collagen accumulation due to the rapid atrial 
pacing, which the group hypothesized as one of the deciding factors that led to sustained 
AF along with glycogen accumulation.
180
 
In similar studies Ausma et al. reported that there was significant electrical 
(shortening of the atrial refractory period) and structural remodeling (in the form of 
glycogen accumulation, loss of contractile apparatus function and twofold increase in 
myocyte cell size) that occurred due to the induction of AF by rapid atrial pacing in 
healthy goat hearts. This study also reported that the electrical and structural remodeling 
initiate within the 48 hours of induction followed by a sustained AF within 1-2 weeks. 






2.2.2 Atrial Fibrillation and Diabetes 
Diabetes has been identified as one of the most important risk factor for atrial 
fibrillation.
5;15
 It has been reported that the risk factor for AF is 1.4-2.2 times higher in a 
diabetic patient compared to a healthy person.
14;19;184;185
 In a population based study, Du 
et al. reported 7.6% of the diabetic patients had baseline AF.
186
 Although the underlying 
mechanisms that cause diabetes induced AF remains elusive, a few of the proposed 
mechanisms include insulin resistance, poor glycemic control, and structural and 
electrical remodeling. 
In a study by Ostgren et al., a combination of insulin resistance and impaired 
glycemic control was identified as a potential mechanism for diabetes induced AF.
19
 It 
was reported that AF patients had prominent insulin resistance whereas, the subjects in 
sinus rhythm did not.
19
  In a similar study it was reported that high fasting blood glucose 
and insulin levels in diabetic patients were correlated with the risk factor for the 
development of AF but not with non-diabetic individuals.
15;184
 The risk factor of AF was 
related to the duration of diabetes and level of glycemic control.
15
 Indeed, Dublin et al. 
reported that the risk of developing AF for a diabetic patient increases approximately 3% 
for each additional year of diabetes duration.
17
 Additionally, AF attacks have been 
associated with periods of hypoglycemia in insulin-dependent T1Dx patients.
187;188
 
Another study by Rigalleau et al. reported major hyperglycemia preceded by AF attack in 
insulin-independent T2Dx patients.
16
 Together the results of these studies
15;17;19;185;189-192
 
suggest that disturbances in glucose and insulin could directly affect the function of the 
atrium, potentially leading to AF. The diabetic myocardium has increased susceptibility 
to ischemic injury which also makes the myocardium vulnerable to AF.
5
 Atrial fibrosis 
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and remodeling is one of the major risk factors for AF, as demonstrated by Kato et al. 
when they reported widespread fibrotic deposits in the myocardium of diabetic rats. It 
was suggested that the fibrotic deposits could serve as anchoring points for reentry 
circuits and attenuate forward wave propagation in the atrium. In the same study a single 
electrical impulse was able to generate multiple atrial responses, which support the 
hypothesis that a diabetic myocardium is more vulnerable to AF.
14
 Altered gap junction 
activity, which is an alteration in electrical coupling between two adjacent myocytes, has 
been reported as one of the hallmarks of AF. Interestingly, decreased phosphorylation of 
connexin-43 was reported in the atrium of diabetic rats.
193
  This finding suggests that, the 
alteration in gap junction activity could lead to improper signal transduction between the 
atrial myocytes and  cause atrial arrhythmia in the diabetic myocardium.  
2.2.3 Atrial Fibrillation and Advanced Glycation End Products 
During diabetes, Advanced glycation end products (AGEs), are formed by the non-
enzymatic glycation of both intracellular and extracellular proteins in the presence of a 
high glucose concentration.
38
 The level of hyperglycemia, the turnover rate of proteins 
and the extent of oxidative stress are the major factors that play a role on the formation of 
AGEs.
194;195
 As the process of forming a glycated proteins occur over a period of few 
weeks, therefore the proteins with longer turnover rate are more susceptible to glycation 
(such as albumin and hemoglobin).
196
 AGEs are formed when aldehyde or ketone groups 
of reducing sugars (such as glucose, fructose, ribose, etc.) react non-enzymatically and 
form covalent bonds with free amino groups of amino acids (such as lysine, arginine etc.) 
in the protein chain. This reaction is also known as the Millard reaction.
38
  The Millard 
reaction begins with the formation of a reversible Schiff base (1-2 weeks glycation 
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period) which is considered reversible. With longer duration in a Schiff base, 
spontaneous rearrangement can be undergone to form the more stable Amadori products 
(6-8 weeks glycation period).
194
 The proteins bearing the Amadori products are 
considered to be irreversible and are referred to as the glycation products. 
Advanced glycation end products present in the diabetic myocardium also 
participate in major myocardial structural remodeling by upregulating growth factors, 
activating the AGE-RAGE (RAGE: Cellular receptor of AGE) axis and cause interstitial 
fibrosis. 
197
  Begieneman et al. reported increased expression of major AGEs (N
ε
-
carboxymethyl lysine, CML-AGE) in the left atrial appendage (LAA) of AF patients.
50
 In 
addition, increased plasma AGEs have been reported to be associated with incidence of 
AF, independently of diabetes.
50;51
 However, no significant correlation between AGEs 
and the incidence and development of AF have been reported in a recent large population 
based study.
198
 Therefore, whether or not AGE accumulation plays a role in the 
progression of AF remains to be determined.  
AGE also binds with its cellular receptor, RAGE, and activates pro-inflammatory 
pathway that results in the overexpression of pro-fibrotic markers (transforming growth 
factor -1 (TGFβ-1), matrix metalloproteinase -9 (MMP-9), collagen I and III) which has 
been identified as an independent risk factor of AF as it contributes to atrial structural 
remodeling and dilation.
145;166;174;175
 Raposeiras-Roubin et al. conducted a study to 
correlate the activation of AGE-RAGE axis and atrial fibrillation in human AF patients. 
The study reported increased level of soluble RAGE, and AGE in the plasma of both 
diabetic and non-diabetic AF patients. This is probably due to the higher oxidative stress 
associated with other cardiac complications of the AF patients and the activation of AGE-
28 
 
RAGE axis. Increased area and volume of the left atria in the AF patients were also 




2.3 Cardiac Metabolism 
As cardiac myocytes contract constantly, the myocardium requires constant 
source of energy (adenosine tri phosphate, or ATP). Under non ischemic conditions 95% 
of the ATP is generated in the mitochondria by oxidative phosphorylation. The heart 
utilizes 60-70% of the generated ATP for contractile function and the remainder is used 
for the function of various ion pumps. The myocardium has a high ATP hydrolysis and 
turnover rate and very little to no ATP reserve. Under physiological conditions, the rate 
of ATP generated by oxidative phosphorylation is slightly higher than the rate of ATP 
hydrolysis, and, therefore, the total content of ATP remains constant even with large 
energetic demands (intense exercise, acute stress). During resting conditions, a well 
perfused heart uses fatty acid (60-90%) and glucose (10-40%) as an energy substrate. 
However, in the presence of insulin this ratio is reversed, as the heart derives 60-70% 
energy from glucose. These substrates undergo β-oxidation and glycolysis respectively 
and produce Acetyl-CoA as an end product in the mitochondria. The produced Acetyl-
CoA enters the TCA cycle and is converted to NADH. The electron transport chain 




Glucose for the heart is derived either from the blood stream or from the glycogen 
stores within the cardiac myocytes.
202
 As exogenous glucose enters the cell they are 
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rapidly phosphorylated by hexokinase (first regulatory step in glucose metabolism) and 
converted to glucose-6-phosphate. This compound either enters the glycolytic pathway 
(majority) or is converted to glycogen as storage. However, a variable amount of 
exogenous glucose cycles through glycogen prior to entering the glycolytic pathway.
203
 
Glucose-6-phosphate is first converted to fructose-6-phosphate. At this stage 
phosphofructokinase (PFK-1), a key regulatory enzyme, phosphorylates fructose-6-
phosphate to a more stable fructose-6-bisphosphate using one ATP molecule.
204;205
 
Conversion of fructose-6-bisphosphate from fructose-6-phosphate is the rate limiting step 
of the glycolysis process. Fructose-6-bisphospate is eventually converted to pyruvate at 
the cytosol and as pyruvate enters the mitochondria it is used in the production of ATP. 
The glycolysis pathway generates 2 pyruvate molecules from each glucose-6-phosphate 
molecule. Within the mitochondria, the activity of another key enzyme, pyruvate 
dehydrogenase, tightly regulates the production of acetyl-CoA from each of the pyruvate 
molecules. At the end of the oxidative phosphorylation process, 38 molecules of ATP are 
generated for each molecule of glucose.
20;199;204;205
 
The amount of glycogen accumulation in the heart is dependent upon the 
availability of other metabolic substrates (glucose, fatty acid) or stimulation of hormone.  
During fasting, fatty acid oxidation is predominant which inhibits glycolysis and reroutes 
the exogenous glucose/glucose-6-phosphate towards the formation of glycogen.
202;206-208
  
Insulin also increases glycogen synthesis as it facilitates cellular glucose uptake and 
stimulates glycogen synthase activity.
206
 Initiated by the requirement of extra energy and 
increase in work load (e.g. during exercise), glycogenolysis occurs due to the activation 
of glycogen phosphorylase (stimulated by epinephrine).
203;209;210
 In healthy adults, 
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glycogen occupies 2% of the entire volume of the cardiac myocytes and in newborn or 
fetal cells it occupies 30% of the total volume of the cardiac myocytes.
211
 
2.3.1 Abnormal Atrial Metabolism during Atrial Fibrillation   
The mechanisms of persistent atrial arrhythmia and the related metabolic changes during 
atrial fibrillation are not well understood. Atrial fibrillation has been associated with 
modifications in atrial energy metabolism, however, whether alteration in glucose 
metabolism is the cause or consequence of AF remains inconclusive.
118;212-218
 Kondrat’ve 
et al. studied the changes in energy metabolism in the myocardium during acute 
experimental AF on healthy male Wistar rats. They reported that the induced AF (5-10 
mins for 8-10 times) depleted the atrial glycogen storage by activating the glycogen 
phosphorylase system. They hypothesized that this was caused by the increase in need of 
energy consumption to sustain the frequent, but yet inefficient contractions in the 
fibrillating myocardium.
219
 However, in contrast to this study, glycogen accumulation in 
the atrial tissue has been identified as one of the structural remodeling factors that 
increase the pathogenesis of persistent/permanent AF. (Please find details regarding 
glycogen and AF in  section 2.2.1).  
Modifications of atrial energy demand have been associated with AF in both 
human and animal models.
213-215
 However, while some studies reported increased energy 
demand
213;215
 during episodes of AF, others reported impairment in energy production 
and consumption.
212;214;216
 In a quantitative proteomics analysis, Tu et al. attributed the 
impaired energy production in the LAA of AF patients to the downregulation of 
carbohydrate metabolism related proteins.
220
 Key enzymes of the glycolysis pathway 
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such as glucose-6-phosphate and 6-phospho-fructokinase were reported to be 
downregulated in the LAA of AF patients, suggesting an overall impairment of glucose 
metabolism during AF.
220
 Irregularly irregular contraction of the atrial tissue has also 
been associated with increased ADP and AMP-to-ATP ratio in the cell as a marker of 
increased energy expenditure.
140;221;222
 Human AF has also been associated with 
increased cytosolic Ca
2+
 levels and Ca
2+
/calmodulin dependent protein kinase II 
(CAMKII) levels. 
223-227
 Neef et al. reported higher activation of CAMKII resulting in 
increased sarcoplasmic reticulum Ca
2+
 leaks resulting in elevated diastolic Ca
2+
 
concentrations in the right atrial myocardium of human patients with AF.
228
 Activation of 
Ca
2+
-dependent pathways and increased CAMKII 
229;230
 and AMP 
231
 levels have been 
reported to activate AMPK, the cellular regulator of stress related metabolic signaling.
232-
234
 Lenski et al. reported that irregular pacing resulted in the activation of CAMKII and 
AMPK, which enhanced fatty acid uptake, increased lipid accumulation and decreased 
glucose uptake in atrial myoctes.
12
 AMPK activation decreases myocardial glucose 
uptake by decreasing the expression of SNAP-23 (synaptosomal-associated protein 23) 
which is a crucial regulator of GLUT4 (see section 2.5.1) vesicular trafficking to the cell 
surface.
235;236
 It has been reported that in the left atria of AF patients, GLUT4 trafficking 
to the cell surface was impaired, whereas the expression of total GLUT4 expression was 
increased. The same study also reported increased glycogen accumulation and major 
myocardial remodeling, in the left atria of the AF patients. However, whether or not this 
increase was AMPK dependent remained inconclusive.
12
 Despite the efforts of these 
studies, mechanisms of arrhythmia related to the altered metabolism in the atria are still 
not well understood. 
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2.3.2 Cardiac Glucose Transport  
Glucose is a major energy substrate for the heart, which generates 30% of its total 
energy from glucose oxidation.
237
 Therefore, cardiac glucose uptake is crucial for proper 
cardiac function. The first step of glucose uptake is the transport of glucose from the 
blood stream across the plasma membrane and into the cell. This is conducted by a 
specialized transporter of glucose known as the GLUT family. The GLUTs are stored 
intracellularly (inactive location) or located at the plasma membrane (active location). 
The intracellularly stored GLUT vesicles are translocated to the plasma membrane upon 
action from an external stimulus, such as insulin. Translocation of GLUTs to the plasma 
membrane to the cell surface is the rate limiting step of glucose utilization. The different 
members of the GLUT family and regulation of GLUT trafficking via insulin signaling 
pathway are discussed below in detail.  
2.3.3 Glucose Transporters (GLUTs) 
Glucose transporters (GLUTs), members of a specialized family of membrane 
transporters, are responsible for the disposal of exogenous glucose.  It has been reported 
that, at least one GLUT isoform is present in every cell type of the body, therefore, 
GLUTs are recognized as key regulators of whole body glucose homeostasis.
23
 Following 
glucose uptake, glucose is either stored as glycogen or oxidized to produce energy.
238
 So 
far 14 sugar transporter proteins have been identified in the human genome.
23
 The 
distribution of the glucose transporters is widespread, including the skeletal muscle, 
adipose tissue, liver, intestine, kidney, peripheral blood vessels, endothelial cells in the 
blood brain barrier, brain and the heart.
239
 The kinetics of these transporters differs 
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according to their substrate location that reflects their specific roles in cellular and whole 
body glucose homeostasis.
240
 The GLUT superfamily has been divided into 3 classes: 
Class I (GLUTs 1-4 and GLUT 14), Class II (GLUTs 5, 7, 9 and 11) and the novel Class 
III (GLUT 6, 8, 10, 12 and HMIT).
23
 Of the Class I, transporters GLUT-1 and -4 have 
been extensively studied. GLUT1 is the major transporter of glucose across the 
endothelial cells in blood brain barrier and erythrocytes.
241
 GLUT1 is mainly located at 
the cell surface and serves as a basal transporter. GLUT2 is mostly found in the liver and 
pancreatic beta cells, and functions as part of the glucose sensor system during the 
postprandial absorptive state.
239
 GLUT3 is mostly present in neurons (both dendrites and 
axons) and testis.
240
  GLUT4 is the major insulin-responsive isoform and present mainly 
in skeletal muscle, adipose tissue and the heart. Among these glucose transporters, 
GLUT2 has lower affinity for glucose compared to GULT 1, 3 and 4.
239
 GLUT-5 and -11 
are mainly the transporters of fructose in the small intestine, kidney and skeletal 
muscle.
238
  Among the glucose transporters, insulin-dependent GLUT4 is the major 
mediator of glucose removal from the blood stream and is a key regulator of glucose 
homeostasis.
242
 However, recent findings by Katz et al. report that GLUT4 knockout 
mice do not develop hyperglycemia, suggesting the presence of other insulin sensitive 
isoforms.
25
 Therefore, there have been new studies that investigate the novel Class III 
isoforms, particularly GLUT-8 and -12. Both of these isoforms have been reported in 
skeletal muscle, adipose tissue and the cardiac tissue.
23
 In the cardiac tissue, GLUT12 has 
been identified as a basal glucose transporter.
37
 However, GLUT8 is not well 
characterized in the heart and whether or not this isoform is insulin responsive is yet to be 
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determined. In the current study, we investigate the role of GLUT-4 and -8 in atrial 
glucose uptake in the context of diabetes. 
2.3.3.a Glucose transporter 4 (GLUT4) 
 The insulin-sensitive GLUT4, 50-60 kDa glycoprotein containing 12 
transmembrane domains, is the principal glucose transporter protein in the mammalian 
tissue.
243;244
  GLUT4 is responsible for the glucose uptake into the cells, supplying 
cellular glucose for ATP production, and for a wide range of anabolic reaction.
243
 In 
contrast to the other GLUT isoforms, which are primarily localized in the plasma 
membrane, only 3-10% of the total GLUT4 is present on the membrane during the basal 
or unstimulated state.
244
 They are mainly sequestered into specialized storage vesicles 
that remain within the cytosol in the absence of insulin stimulation.
242
 Upon insulin 
stimulation, these vesicles undergo exocytosis and are diffused onto the plasma 
membrane. In addition, the presence of insulin partially inhibits GLUT4 endocytosis and 
compartmentalization.
245-247
 This results in a positive shift of GLUT4 localization in the 
membrane via which glucose can enter the cell through an ATP-independent, facilitative 
diffusion mechanism.
244
 However, this process is reversed, when the circulating insulin 
level declines and the membrane bound GLUT4 is endocytosed into the storage 
vesicles.
244
  Numerous studies have identified GLUT4 storage in the Trans Golgi 
network, clathrin coated vesicles and endosomes.
242
 However, the majority of the GLUT4 
is stored in the tubulovesicular elements that lie just beneath the plasma membrane in the 
cytoplasm and are identified as the specialized GLUT4 compartments.
248
 Upon insulin 
activation, the PI3 kinase pathway is activated, leading to the phosphorylation of AS160 
(see section 2.3.4.a). This step is essential for the vesicular trafficking of the GLUT4 
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vesicles. The phosphorylation of AS160 allows the activation of  RabGTP which is 
necessary for the docking and diffusion of the GLUT4 vesicles on the plasma 
membrane.
249
 It has been reported the caveolae lipid rafts serve as the major docking site 
for GLUT4 transporters as 85% of the total plasma membrane bound GLUT4 have been 
found to be localized in the caveolae rafts.
250
 
 During T1Dx, Huang et al. reported impairment in insulin stimulated GLUT4 
trafficking in the myocardium of streptozotocin (STZ)-treated diabetic rats.
251
 Similarly, 
Waller et al. reported a decrease in both total and membrane bound GLUT4 expression in 
the ventricles of STZ-induced diabetic mice. This study also reported impairment in 
GLUT4 translocation to the cell surface upon insulin stimulation.
37
 During type 2 
diabetes (T2Dx), there is a marked reduction in insulin-mediated glucose uptake caused 
by cellular resistance to insulin.
113
 It has been reported in multiple studies that there is a 
substantial down regulation of GLUT4 protein and mRNA levels in adipocytes during 
T2Dx and obesity.
252;253
  In the skeletal muscle, no change in total level of GLUT4 has 
been reported between diabetic and non-diabetic patients.
254-257
 However, significant 
impairment of insulin-stimulated GLUT4 vesicular trafficking has been reported in 
patients with T2Dx.
258-260
  It has been documented that, in skeletal muscle, insulin 
resistance alters sub-cellular localization of GLUT4 storage vesicles to dense membrane 
compartments from which insulin is unable to recruit GLUT to the cell surface.
260
  The 
specific molecular mechanism of such events is yet to be elucidated. Together, these 
studies demonstrate that in skeletal muscle, adipose tissue and the ventricles, there is 
significantly less GLUT4 on the membrane for glucose uptake during diabetes. However, 
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the role and regulation of GLUT4 in the atria during healthy and diabetic conditions 
warrants further investigations. 
2.3.3.b Glucose Transporter 8 (GLUT8) 
Glucose transporter 8 is a novel class III glucose transporter that has been shown 
to be present in substantial quantities in the cardiac tissue and may play a significant role 
in glucose uptake in the heart.
237
 GLUT8 has the highest mRNA level after GLUT4 in the 
myocardium.
27;237
 Unlike the well understood class I transporter GLUT4, the subcellular 
localization, regulation and physiological role of GLUT8 in mammalian tissue is not well 
understood. So far GLUT8 has been reported in the skeletal muscle, adipose tissue, liver, 
spleen, testes, kidney, brain and the cardiac tissue. It has been reported that GLUT8 is a 




The structure of GLUT8 is yet to be well characterized; however, the amino acid 
sequence of GLUT8 exhibits all elements and motifs that are characteristic of sugar 
transporters or GLUTs (i.e. 12 membrane spanning helices, glutamate and arginine 
residues in loops 4 and 10) with a molecular weight of 50 kDa.
29
 It has been reported that 
GLUT8 is predominantly located in intracellular compartments due to the presence of di-
leucine motif in the amino terminus domain.
27;30;31;262
 However, the site of intracellular 
localization of GLUT8 has been widely debated. In the brain hippocampus, GLUT8 is 
reported to be associated with membrane containing intracellular compartments of 
neuronal bodies. The authors reported that upon peripheral insulin stimulation GLUT8 
translocates from the smooth ER to the rough ER in the rat hippocampus. The insulin 
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sensitivity of GLUT8 in other tissue, specifically the cardiac tissue is yet to be 
investigated.  
Whether or not GLUT8 is insulin responsive in the mammalian tissue has not 
been well characterized.
263;264
 Mutation of the di-leucine residues to alanine in the 
GLUT8 structure potentially targets the transporter to the plasma membrane. A similar 
motif is present in GLUT4, which is located in the intracellular compartments and 
translocation to the cell surface upon insulin stimulation. Therefore, it can be speculated 
that GLUT8 has similar translocation potential.
29
 However, the extracellular stimulus that 
may cause GLUT8 translocation to the plasma membrane remains to be identified. 
Insulin-stimulated translocation of GLUT8 to the plasma membrane of blastocysts has 
been reported; however, this mechanism has not been observed in adipocytes. Indeed, 
Lisinski et al. reported that GLUT8 is not insulin responsive in adipocytes. Interestingly, 
the GLUT8 gene expression was down-regulated during glucose deprivation and hypoxia 
in 3T3-L1 adipocytes.
30
  These data suggest that GLUT8 may play a major role in 
glucose homeostasis.  
During diabetes, liver GLUT8 mRNA levels were correlated with the circulating 
insulin. In a study conducted by Gorovits et al. significant decrease of GLUT8 mRNA 
was observed during insulinopenia/hyperglycemia, whereas significant increase of 
GLUT8 mRNA was observed in hyperinsulinemia/hyperglycemia, suggesting a 
regulatory role of insulin in GLUT8 mRNA expression.
30
   In addition,  it was reported 
that STZ-induced diabetes induced significant decrease in GLUT8 mRNA expression in 
hepatocytes with a paradoxical increase in GLUT8 protein levels.
30
 Piroli et al. reported 
that hyperglycemic and insulinopenic rats (following STZ injection) expressed lower 
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levels of GLUT8 and ER GLUT8 trafficking in the hippocampus.
263
 DeBosch et al. 
suggested that GLUT8 caused deleterious metabolic effects during high fructose diet. 
Their studies reported that, GLUT8 deficient mice were protected against high-fructose-
diet-induced fructose intolerance, high-fat-diet-induced obesity, insulin resistance, and 
hypoinsulinemia compared to wild type controls.
261;265-267
 Together, these studies suggest 
that GLUT8 plays an important role in metabolic and homeostatic functions. Although 
the heart is one of the main organs to utilize glucose, to our knowledge there is no study 
that investigates the functional role of GLUT8 in the cardiac tissue, specifically in the 
atria during both heathy and diabetic conditions.   
2.3.4. Insulin Signaling Pathway 
During the post prandial absorptive state, as the blood glucose level increases, the 
pancreatic beta cells release insulin into the blood stream. Insulin modulates cellular 
glucose uptake by binding to the insulin receptor
4
. The binding of insulin to its receptor 
initiates an intracellular signaling cascade, which translocate the insulin sensitive glucose 
transporters (GLUTs) from the cytosol to the plasma membrane. As the glucose 
transporters translocate to the plasma membrane (active site), glucose molecules from the 
blood stream enter the cells via the GLUTs.
242
 The intracellular signal transduction 
initiated by ligand binding of insulin is known as the insulin dependent pathway or the 
PI3 kinase (phosphoinositide 3 kinase) pathway. 
  2.3.4.a. Signal Transduction Pathway: 
The insulin receptor on the cell surface is a member of the large transmembrane 
tyrosine kinase receptor family (RTKs). It is a heterotrimeric structure with two 
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extracellular (α) and two intracellular (β) subunits.
268
 Insulin binds to the extracellular 
domain of the insulin receptor. This causes a conformational change in the receptor’s 
intracellular domain, followed by auto phosphorylation at the intracellular β subunits of 
the tyrosine kinase domain.
242
 Cytosolic scaffolding substrate protein IRS-1 binds to the 
phosphorylated domain of the receptor. This IRS-1 substrate serves as a binding and 
activation site for the effector protein PI3 kinase.
268
  The PI3 kinase takes part in 
numerous cellular responses, such as anti-apoptosis, protein synthesis and glycogen 
synthesis. Apart from insulin, PI3K is attributed as the most important enzyme for the 
insulin stimulated glucose transport.
269
 As PI3 kinase binds to the phosphorylated site of 
the IRS, it phosphorylates phosphatidyinositol (4,5) bisphosphate or PIP2 to 
phosphatidyinisitol (3,4,5) trisphosphate or PIP3. PIP3 binds to the PH domain of the 3-
phosphoinositide dependent protein kinase-1 (PDK-1) and protein kinase B (also known 
as Akt), localizing them to the cell surface.
268
 At the membrane, PDK-1 phosphorylates 
Akt at threonine 308 (Th 308) residues, which is located in the kinase domain of the Akt 
activation loop. The full activation of Akt requires a further phosphorylation of serine 
473 (s473) residues by mTOR2 (rapamycin insensitive companion of mTOR).
268;269
  
Activated Akt phosphorylates a downstream protein AS160 (Akt substrate protein of 160 
kDA) which is essential for the exocytosis of GLUT4 to the cell membrane. AS160 is the 
most distal protein in the insulin-mediated GLUT trafficking pathway and plays a major 
regulatory role. Under basal conditions, AS160 retains the GLUT vesicles at their 
intracellular location by its GTPase activating protein (GAP domain of the members of 
Rab G protein family). Unstimulated Rab is maintained in its inactive GDP form, while 
phosphorylation of AS160 (at 6 different phospho-Akt-substrate (PAS) sites) inhibits its 
40 
 
GAP activity and elevates the GTP form of Rab. It has been suggested that GLUT 
vesicular translocation to the plasma membrane requires the active GTP bound 
Rab.
23;249;268;269
   Figure 2.1 briefly illustrates the different events of the insulin-stimulated 
PI3 kinase pathway.  It is important to note that, the initiation of the signaling cascade by 
the activation of the insulin receptor not only increases GLUT4 exocytosis at the 
membrane, it also attenuates GLUT4 endocytosis causing an enhanced re-distribution of 
GLUT4 protein at the plasma membrane, facilitating cellular glucose uptake.
270
 Although 
the role of the downstream insulin signaling pathway regarding GLUT4 trafficking has 
been extensively studied in the skeletal muscle and adipose tissue, it not well defined in 
the cardiac tissue., 
242;249;268-271
 In addition the role of the downstream insulin signaling 












Figure 2.1: Insulin stimulated PI3K pathway and GLUT-4 translocation. The figure 
illustrates the activation of the PI3K pathway by the ligand binding of the insulin 
receptor, followed by the phosphorylation of Akt at Th308 and s473 leading to the 


















2.3.4.b Protein Kinase B AKT 
Serine/threonine kinase Akt, also known as the protein kinase B (PKB), is a 
central player in multiple cellular processes, such as glucose metabolism, cell survival, 
cell proliferation and cell cycle progression.
272
The Akt subfamily consists of 3 isoforms 
(Akt1, Akt2 and Akt3) each with three functional domains: an N terminal pleckstrin 
homology (PH) domain, a protein kinase domain and a C- terminal hydrophobic 
phosphorylation site.
272
 Among the three isoforms, Akt 2 is highly expressed in the 
striated muscle, adipose tissue and the brain. Akt activation is dependent on the PI3K 
signaling pathway and subsequent phosphorylation at Th308 and s473 residues.
273
 
Phosphorylated Akt regulates the function of many cellular proteins involved in 
metabolism, survival/apoptosis and angiogenesis.
273
  
 Akt is a key regulator of glucose uptake by stimulating the translocation of 
GLUT4 and the survival and proliferation of insulin secreting pancreatic beta cells. Over 
expression of phosphorylated Akt has been reported to significantly increase overall 
pancreatic beta cell mass, by increasing both cell size and number; thereby enhancing the 
insulin secretory capacity.
274
 Conversely, a reduction in Akt phosphorylation has been 
reported in insulin resistant individuals. Akt also participates in the activation of NF-ΚB 
by tumor necrosis factor-α (TNFα) by phosphorylating inhibitory protein IΚBα.
275;276
 
  Due to the major role of Akt in the insulin signaling pathway, Akt has been 
widely studied during both insulin deficient type 1 diabetes (T1Dx) and insulin resistant 
type 2 diabetes (T2Dx). According to current literature, during T1Dx insulin signaling is 
normal or slightly affected due to the hyperglycemia. It has been reported by 
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Gerhardinger et al. that low dose insulin stimulation rescues Akt phosphorylation in the 
retina of STZ-induced rats.
277
 Laviola et al. reported that Akt expression was unchanged 
in the myocardium of STZ-induced diabetic rats.
278
 However, in another study by 
Dobryzynski et al. it was reported that insulin-deficient STZ diabetic rats demonstrated 
reduction in baseline Akt activity in the cardiac tissue.
279
  
  During T2Dx, Krook et al. first reported impairment in Akt phosphorylation in 
the skeletal muscle tissue of insulin resistant rats and biopsies from T2Dx patients.
280;281
 
Similarly, there was significant impairment in Akt phosphorylation (at s473 site) in the 
skeletal muscle and adipose tissue of db/db mice, although its total protein expression 
remained unchanged.
282
 Karlsson et al. reported that an attenuation of insulin induced 
AS160 phosphorylation in human skeletal muscle during hyperinsulinemia, the hallmark 
of T2Dx. This impairment of insulin action on AS160 was associated with reduced 
phosphorylation of Th308.
258
 Similarly, Akt activation was impaired in adipocytes of 
obese human T2Dx patients and T2Dx rodents.
283;284
 Defects in GLUT4 translocation 
was also reported to be associated with defective Akt phosphorylation.
285;286
  Cho et al. 
used an Akt2 knockout mouse model to investigate the role of Akt during insulin 
resistance, and reported that the Akt2 null mice displayed hyperglycemia, impaired 
glucose tolerance and hyperinsulinemia.
287
 Together all of the above studies strongly 
suggest the crucial role of Akt in the insulin signaling pathway and GLUT trafficking. 
Despite the crucial role of Akt in GLUT trafficking and glucose uptake, there have been 
very few studies that investigate its functional role in the cardiac tissue during both T1Dx 
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Although diabetes has been identified as a major risk factor for atrial fibrillation, little is 
known about glucose metabolism in the healthy and diabetic atria. Glucose transport into the 
cell, the rate-limiting step of glucose utilization, is regulated by the Glucose Transporters 
(GLUTs). Although GLUT4 is the major isoform in the heart, GLUT8 has recently emerged as 
a novel cardiac isoform. We hypothesized that GLUT-4 and -8 translocation to the atrial cell 
surface will be regulated by insulin and impaired during insulin-dependent diabetes. GLUT 
protein content was measured by Western blotting in healthy cardiac myocytes and type 1 
(streptozotocin-induced, T1Dx) diabetic rodents. Active cell surface GLUT content was 
measured using a biotinylated photolabeled assay in the perfused heart. In the healthy atria, 
insulin stimulation increased both GLUT-4 and -8 translocation to the cell surface (by 100 % 
and 240 %, respectively, P<0.05). Upon insulin stimulation, we reported an increase in Akt 
(Th308 and s473 sites) and AS160 phosphorylation, which was positively (P<0.05) correlated 
with GLUT4 protein content in the healthy atria. During diabetes, active cell surface GLUT-4 
and -8 content was downregulated in the atria (by 70 % and 90 %, respectively, P<0.05). Akt 
and AS160 phosphorylation was not impaired in the diabetic atria, suggesting the presence of 
an intact insulin signaling pathway. This was confirmed by the rescued translocation of GLUT-
4 and -8 to the atrial cell surface upon insulin stimulation in the atria of type 1 diabetic subjects. 
In conclusion, our data suggest that: 1) both GLUT-4 and -8 are insulin-sensitive in the healthy 
atria through an Akt/AS160 dependent pathway; 2) GLUT-4 and -8 trafficking is impaired in 
the diabetic atria and rescued by insulin treatment. Alterations in atrial glucose transport may 
induce perturbations in energy production, which may provide a metabolic substrate for atrial 




Diabetes mellitus is a serious metabolic disorder affecting 387 million people 
worldwide 
2;60
. Diabetes has now reached epidemic levels and has been identified as the 
7th leading cause of death in the USA 
2;3
. Hyperglycemia, the hallmark of diabetes, results 
from an impaired glucose uptake due to a lack of insulin production by pancreatic beta 
cell (type 1) or lack of insulin action (type 2). Diabetes results in multiple organ 
dysfunction including cardiomyopathy, coronary artery disease and atrial fibrillation. 
4;5;14;288
 
Glucose is a major energy substrate for the heart, which generates ~30 % of its 
total energy from glucose oxidation during physiological condition.
21
 Therefore, cardiac 
glucose uptake and utilization is crucial for proper cardiac function. This is germane to 
the fact that the atria, which is the pacemaker of the heart, significantly contributes to the 
overall cardiac function. Although the rate of glucose utilization in the heart is greater 
than in other tissue, little is known about glucose metabolism in the atria during both 
healthy and disease states.
20
 Glucose transport into the cell is the rate limiting step of 
glucose utilization and is regulated by a family of membrane proteins known as Glucose 
Transporters (GLUTs).
289
 Although GLUT4 (from the class I of GLUTs) is the main 
cardiac isoform (approximately 70 % of the total cardiac GLUTs), recent evidence 
suggests that GLUT8, one of the most recently discovered isoforms in the class III, is 
also expressed in the heart 
27;29-31
. The GLUT8 mRNA expression is reported to be the 
highest (i.e., ~7% of total GLUTs) in the murine left ventricle, following GLUT4 and 
GLUT1. In addition, it has been reported that there was a significant upregulation of 





there is no study that relatively quantifies the abundance of GLUT8 protein expression in 
the heart. Although GLUT8 has been reported to be an insulin-dependent isoform in 
blastocysts 
31
, its functional role in the myocardium is yet to be determined. Whereas 
some other isoforms have been referred to as basal GLUTs located primarily at the cell 
surface (i.e., GLUT1, GLUT12), the translocation of the main GLUT protein, GLUT4, 
from an intracellular sequestration inactive site to the plasma membrane (active site) is 
largely regulated by insulin-dependent processes, although other factors can alter 
myocardial glucose transport 
24;290
. Importantly, GLUT4 trafficking has been shown to 
precede glucose transport in the insulin-sensitive tissues 
291-293
. In skeletal muscle, 
following insulin stimulation, activation of IRS-1 protein induces the activation of several 
kinases, which in turn recruit the pivotal serine/threonine protein kinase, namely, Akt. 
The activated Akt phosphorylates a downstream protein AS160 (an Akt substrate protein 
of 160 kDa) which is essential for the exocytosis of GLUT4 to the plasma membrane 
271
. 
Although the downstream insulin signaling pathway has been studied in the skeletal 
muscle, it is yet to be characterized in the heart, especially in the atria. Better 
understanding of the role and regulation of glucose transport in the healthy and diabetic 
atria will give novel insights in understanding the pathophysiology of diabetes. 
It has been well documented that there is a regional heterogeneity between the 
atria and ventricles regarding their structure and function. Therefore, one could 
hypothesize that the differences in contraction and flow distribution pattern between atria 
vs. ventricle may also contribute to the regional metabolic heterogeneity 
33;294
. However, 
the majority of the studies that have investigated cardiac energetics have studied global or 
left ventricular changes 
37;295
. A recent study from our group suggested an impairment of 
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glucose transport in the atria of a canine model of heart failure 
294
. However, in this 
model, heart failure was induced by rapid ventricular pacing, which may have had a 
profound effect on metabolism.  Therefore, the role of glucose uptake and utilization in 
the healthy and diseased atria has received little attention. In the current study, we 
hypothesized that 1) the major cardiac GLUT isoform, GLUT4, and the novel GLUT 
isoform, GLUT8, will be regulated by insulin in the atria and 2) GLUT translocation will 
be impaired during diabetes. The enclosed study provides novel insights into the 
expression and regulation of insulin-sensitive GLUTs in the atria, which could lead to a 
better understanding of the uptake of glucose, a major metabolic substrate for the heart. 
MATERIALS AND METHODS 
Animals 
Healthy and insulin-deficient type 1 diabetic (T1Dx) FVB/N mice were used, as 
previously described 
37;295-297
. Briefly, type 1 diabetes was induced at 10–12 weeks of age 
by 3 consecutive doses of freshly prepared steptozotocin (STZ, 65-95 mg/kg IP every 48 
hours, diluted in citrate buffer), while the control group received placebo injection (citrate 
buffer). All mice were fed a standard diet to maintain body weight (10 % kcal from fat) 
for the duration of the study. Diabetes was confirmed by measuring venous blood glucose 
concentration (facial vein) at baseline and every week for both groups, using a 
glucometer (Bayer Contour, Tarrytown, NY) on mice fasted overnight for 8 hours. Fasted 
plasma serum insulin was measured in duplicate using an ELISA kit (Millipore). Eight 
weeks after the induction of diabetes, animals were deeply anesthetized and the heart was 
rapidly removed and underwent a retrograde perfusion using a Langendorff apparatus. 
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All the procedures of this study were approved by the Oklahoma State University 
Institutional Animal Care and Use Committee (#VM-12-3). 
Myocyte isolation 
In order to measure protein expression of GLUTs and the insulin signaling 
pathway in atrial myocytes, isolation of myocytes from healthy adult rats was performed 
by retrograde perfusion of the heart using a Langendorff apparatus, as previously 
described 
37;295-298
. Atrial and ventricular myocytes were obtained by enzymatic perfusion 
of collagenase (Worthington labs, NJ), where a minimum yield of 70% live cells were 
considered acceptable. Both atrial and ventricular myocytes were incubated with or 
without (basal) insulin (0.01µM, for 1 hour at room temperature). 
Protein extraction 
Total and crude extracts of membrane-enriched protein lysates of atrial and 
ventricular myocardium were prepared as previously described 
37;295-297
. Briefly, total 
protein lysates from fresh atrial and ventricular myocytes/tissue were collected by 
incubating the myocytes/tissue with lysis buffer (RIPA, Thermo fisher Scientific). 
Samples were centrifuged at 3000 g for 25 min, and the supernatant was stored at − 80 °C 
until further analysis. Crude membrane protein extracts were collected from frozen tissue 
samples that were homogenized in buffer containing (mM): sucrose 210, NaCl 40, EDTA 
2, HEPES 30, and protease inhibitor (Sigma, St. Louis, MO). The homogenate was 
incubated with sodium pyrophosphate 58 mM and KCl 1.17 mM. Crude membranes were 
then recovered by centrifugation at 100,000 g for 90 min at 4°C. Pellets were re-
suspended with a cell lysis buffer (RIPA, Thermofisher Scientific). Samples were 
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centrifuged at 3000 g for 25 min, and the supernatant was stored at − 80 °C until further 
analysis.  
Western immunoblotting 
Equal amounts of protein (5-20 μg) were resolved in an 8-12 % SDS-
polyacrylamide gel and electrophoretically transferred (BioRad) to a polyvinyl-idine 
fluoride membrane (Biorad), as previously described 
37;294-297;299;300
. After blocking (1-5 
% non-fat dry milk or 2 % goat serum albumin), membranes were incubated with 
optimally diluted primary antibodies overnight (polyclonal rabbit anti-human GLUT4, 
1:750, AbD Serotec 4670-1704; polyclonal rabbit anti-human GLUT8, 1:500, Bioss bs-
4241R; monoclonal rabbit anti-mouse total Akt, 1:1000, Cell Signaling 4061; monoclonal 
rabbit anti-human phosphorylated Akt s473, 1:1000, Cell Signaling 4060; monoclonal 
rabbit anti-mouse phosphorylated Akt Th308, 1:1000, Cell Signaling 2965; monoclonal 
rabbit anti-human total AS160, 1:1000, Cell Signaling 2670 and polyclonal rabbit anti-
human phosphorylated AS160, 1:1000, Cell Signaling 9611) followed by a 1 hour 
incubation of appropriate secondary antibodies conjugated to horseradish peroxidase (for 
total and phosphorylated Akt and AS160, Cell Signaling 7074, 1:2000, polyclonal goat 
anti-rabbit; for others, GE Healthcare NA934V, polyclonal donkey anti-rabbit). Primary 
antibodies were chosen based on their 100 % sequence homology with the protein of 
interest in rodents, and validated against a positive control (i.e., tissue, peptide).  
Antibody-bound transporter proteins were quantified by enhanced chemiluminescence 
reaction (KPL) and autoradiography. Band density and molecular weight were quantified 
using GelPro Analyzer (Media Cybernetics). The data was expressed relative to 
appropriate controls. Equal protein loading was confirmed by reprobing each membrane 
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with Calsequestrin monoclonal IgG (Thermo-Scientific PA1-903, 1:2500, polyclonal 
rabbit anti-dog).  
Quantification of GLUT translocation to the cell surface 
Following a 1 hour Langendorff perfusion (with and without 0.7 nm insulin), both 
healthy and T1Dx atria and ventricles were photolabeled with the cell surface 
impermeant biotinylated bis-glucose photolabeling reagent (bio-LC-ATB-BGPA, 300 
μM, Toronto Research Chemicals, ON, Canada), of which the hexose group interacts 
specifically with the extracellular binding site of GLUT. The photolabeled reagent was 
infused into the intact heart through the aorta before cross-linkage to cell surface GLUTs 
using a Rayonet photochemical reactor (340 nm, Southern New England UV), as 
previously described 
37;295;301
. Protein extraction was immediately followed with 
homogenization and ultracentrifugation (227,000 g, 50 min at 4°C). Recovery of 
photolabeled (cell surface) GLUTs from total cardiac membranes (200 μg) was achieved 
using streptavidin isolation (bound to 6% agarose beads) to facilitate separation of non-
cell surface GLUTs ("unlabeled" or intracellular fraction that remains in the supernatant) 
from cell surface GLUTs ("labeled" or sarcolemmal fraction). The labeled GLUTs were 
then dissociated from the streptavidin by boiling in Laemmli buffer for 30 min prior to 
SDS-PAGE and subsequent immunoblotting with GLUT antibody. Proteins from the 
labeled fraction were quantified by densitometry relative to the positive control, as 
previously described 
37;295;299;300






Normality and homogeneity of data were tested using Shapiro-wilk and Levene 
test, respectively. Differences between means were assessed using Student’s t-tests, one 
or two-way analysis of variance (treatment and/or tissue) for in vitro measurements, as 
appropriate. Repeated measured 2 way ANOVA was performed with Student Newman 
Keuls post-hoc test for the in vivo measurements. If not normally distributed, the data was 
analyzed with a Mann-Whitney or Friedman test. Correlations were analyzed by linear 
regression. Statistical significance was defined as P<0.05. Data are presented as mean ± 
SE. 
RESULTS 
Regional heterogeneity of GLUT in the healthy myocardium 
Since glucose transport has not been well characterized in the atria, we first quantified 
total GLUT-4 and -8 protein content in the healthy myocardium. Our results indicated a 
significant regional heterogeneity of both the GLUTs in the atria vs. the ventricle. Total 
GLUT4 protein content was significantly greater in the isolated rat atrial myocytes 
compared to the ventricle (Fig 1A). In contrast, there was significantly greater GLUT8 
content in the healthy ventricle compared to the atria (Fig 1B). In order to investigate the 
insulin sensitivity of the GLUTs in the healthy atria, we then measured protein content of 
GLUT-4 and -8 upon insulin stimulation in isolated rat atrial myocytes. Our results 
indicated an increase in total GLUT-4 and -8 total protein content (by 44 % and 60 % 
respectively, P<0.05) upon insulin stimulation (Fig 1C and 1D). In order to measure 
GLUT translocation to the cell surface, the rate limiting step in glucose uptake, we used 
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the biotinylation photolabeled assay in the intact perfused mouse heart to reliably 
quantify the proportion of active cell surface GLUTs at the atrial and ventricular cell 
surface (Fig 1E and 1F). Our results confirmed the regional heterogeneity of GLUT4 and 
GLUT8 in the atrial and ventricular cell surface, showing significantly greater cell 
surface GLUT4 content in the atria and greater cell surface GLUT8 content in the 
ventricle respectively (Fig 1E and 1F). To further determine whether GLUT-4 and -8 are 
insulin-sensitive, the biotinylation photolabeled assay was performed in the heart 
perfused with or without (basal) physiological concentration of insulin. Upon insulin 
stimulation, there was significant increase in cell surface GLUT-4 and -8 content in both 
the atrial (by 100 % and 240 % vs. basal condition, respectively, P<0.05) and ventricular 
cell surface (by 97 % and 40 % vs. basal condition, respectively, P<0.05), indicating that 
both GLUT-4 and -8 are insulin-sensitive in the atria and ventricle. Interestingly, the 
response to insulin was greater in the atria compared to the ventricle, with an increase in 



























Fig 1: Regional heterogeneity of the insulin-sensitive GLUT4 and GLUT8 in the 
healthy myocardium.  
Higher total protein expression of A) GLUT4 and lower B) GLUT8 content in the 
healthy atrial compared to ventricular myocytes. Top panels: representative Western 
blot from total lysate of isolated rat myocytes; calsequestrin (CLSQ) was used as a 
loading control; representative bands were obtained from the same membrane. Bottom 
panels: Mean ± SE of total GLUT protein content (values expressed relative to atria; 
n=6/group); * P<0.05 vs. atria. GLUT: glucose transporters. Insulin stimulation 
increases C) GLUT4 and D) GLUT8 protein content in the healthy atrial myocytes. 
Top panels: representative Western blot from total lysate of isolated rat myocytes, 
calsequestrin (CLSQ) was used as a loading control. Bottom panels: Mean ± SE of total 
GLUT protein content (values expressed relative to basal atria; n=8-11/group); # P<0.05 
vs. basal. Insulin stimulates E) GLUT4 and F) GLUT8 trafficking to the atrial cell 
and ventricular cell surface. Top panels: representative Western blot. Bottom panels: 
Mean ± SE of cell surface GLUT protein content (values expressed relative to labeled 
basal atria; n=3-4/group); # P<0.05 vs. basal; *P<0.05 vs. atria. Methods: Cell surface 
GLUT measured using biotinylated photolabeling technique in the intact perfused 




Analysis of downstream insulin signaling pathway in the healthy atria 
In order to investigate the mechanisms regulating the translocation of GLUT-4 
and -8 to the atrial cell surface, we then explored the downstream insulin signaling 
pathway, by incubating rat atrial myocytes with and without (basal) insulin. We reported 
a significant increase in the phosphorylation of Akt (at s473 and Th308 sites) and AS160 
upon insulin stimulation (Fig 2A and 2C). In addition, we reported a significant positive 
linear correlation between total GLUT4 protein content (Fig 1C) and phosphorylation of 
Akt (Fig 2B), as well as between total GLUT protein content (Fig 1C and 1D) and AS160 
activation (Fig 2D). However, no significant change was observed when phospho Akt 
(data not shown) and phospho AS160 (Fig 2C) were compared to total Akt and AS160, 
respectively. Collectively these data suggested that Akt and/or AS160 phosphorylation 












Fig 2: Analysis of the downstream insulin signaling pathways in the healthy atria. 
 A) Insulin stimulates phosphorylation of Akt at s473 and Th308 site in atrial 
myocytes. Top panels: representative Western blot from total lysate of isolated rat atrial 
myocytes incubated with (0.01µM) and without (basal) insulin; calsequestrin (CLSQ) 
was used as a loading control. Bottom panels: Mean ± SE of protein expression (values 
expressed relative to basal; n=5/group);  # P<0.05 vs. basal. B) Significant linear 
positive linear correlation between Akt phosphorylation (at s473 and Th308 site) 
and GLUT4 expression in the healthy atria. C) Insulin stimulates phosphorylation of 
AS160 in atrial myocytes. Top panels: representative Western blot from total lysate of 
isolated rat atrial myocytes; calsequestrin (CLSQ) was used as a loading control. Bottom 
panels: Mean ± SE of protein expression (values expressed relative to basal; n=6-
8/group); # P<0.05 vs. basal. D) Significant linear correlation between AS160 




Alteration in GLUT expression and trafficking during type 1 diabetes 
In order to investigate alterations in glucose transport during diabetic conditions, 
we used an insulin-deficient diabetic animal model (T1Dx). As expected, within 1 week 
after injection, STZ-treated animals developed hyperglycemia (i.e., [glucose]>200 
mg/dl), which persisted throughout the experimental period; while the control group 
remained euglycemic (Fig 3A). There was no difference in body weight between groups, 
although both control and diabetic mice weighted more (P<0.05) at the end of the 
experimental period (Fig 3B). In addition, serum insulin level was significantly lower in 
diabetic compared to control mice, confirming that STZ administration destroyed the beta 
cells of the pancreas (Fig 3C). 
We then quantified GLUT-4 and -8 total protein expressions in a crude membrane 
enriched extract of the mouse atria (Fig 4A and 4B). Our results indicated a significant 
decrease in GLUT-4 and -8 total protein content in the type 1 diabetic group compared to 
healthy controls. To accurately differentiate plasma membrane-associated GLUT4 from 
intracellular membrane-associated GLUT4, we used the biotinylated assay in the intact 
perfused atria. We observed a down-regulation of atrial cell surface GLUT-4 and -8 by 70 
% and 88 %, respectively, in diabetic animals compared to healthy controls (P<0.05, Fig 4C 
and 4D). Furthermore, we quantified the proportion of GLUT located at the cell surface 
compared to the intracellular pool for both GLUT-4 and -8 (Fig 4E and 4F). As expected, under 
basal conditions, GLUT4 cell surface fraction was 26 % and 17 % of the intracellular fraction 
during healthy and diabetic condition, respectively (P<0.05). Similarly, under basal conditions, 
GLUT8 cell surface fraction was 25 % and 5 % of the intracellular fraction during healthy and 
diabetic condition respectively (P<0.05, Fig 4E and 4F). Therefore, our results demonstrated a 
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significant down-regulation of total protein expression and trafficking to the atrial cell surface 









































Fig 3: Validation of the insulin-deficient (type 1) diabetic animal model.  
A) Mean ± SE venous blood glucose concentration obtained at baseline and up to 8 weeks in 
type 1 diabetic (T1Dx) and age-matched control (Con) mice (n=9-11/group). B) Mean ± SE 
body weight obtained at baseline and up to 8 weeks after induction of type 1 diabetes (n=9-
11/group). C) Mean ± SE serum insulin concentration obtained at 8 weeks after induction of 






























Fig. 4: Alteration of the trafficking of the insulin-sensitive GLUTs in the diabetic 
atria.  
Decreased atrial A) GLUT4 and B) GLUT8 content during type 1 diabetes (T1Dx). 
Top panels: representative Western blot from crude membrane extract of perfused 
mouse atria, calsequestrin (CLSQ) was used as a loading control. Bottom panels: Mean 
± SE of GLUT protein content (values expressed relative to control; n=7-8/group).  
Type 1 diabetes decreased C) GLUT4 and D) GLUT8 trafficking to the atrial cell 
surface. Top panels: representative Western blot. Bottom panels: Mean ± SE of cell 
surface GLUT protein content (values expressed relative to control; n=4-5/group). 
Majority of E) GLUT4 and F) GLUT8 is intracellular under basal conditions 
(mean ± SE, values expressed relative to control labeled, n=5/group). Methods: Intact 
perfused mouse hearts were photolabeled with bio-LC-ATB-BGPA to determine the 
amount of cell surface (L: labeled fraction) and intracellular (UL: unlabeled fraction) 





Role of insulin in regulating GLUT trafficking to the atrial cell surface during type 
1 diabetes 
Despite intensive research during the last few decades (primarily in skeletal 
muscle and adipose tissue), the pathogenic cause of altered glucose transport during 
diabetes remains elusive. Therefore, we further analyzed the possible alteration in the 
downstream insulin signaling pathway under diabetic conditions, to understand whether or not 
the impairment in GLUT trafficking can be attributed to the defective insulin signaling 
pathway. Interestingly, our results indicated no alteration in the phosphorylation of either Akt 
or AS160 in diabetic subjects (Fig 5A and 5B) compared to the controls. Using the 
biotinylation assay in the intact perfused mouse atria, we further observed a rescued trafficking 
of both GLUT-4 and -8 to the atrial cell surface upon in vitro insulin stimulation in the diabetic 
atria (Fig 5C and 5D). Collectively, the data suggested an intact insulin signaling pathway in 










Fig. 5: Intact insulin signaling pathway in the atria of insulin-deficient diabetic animals. 
Type 1 diabetes (T1 Dx) did not alter A) Akt or B) AS160 phosphorylation in the atria. 
Top panels: representative Western blot from total lysate of mouse atria; calsequestrin 
(CLSQ) was used as a loading control. Bottom panels: Mean ± SE of protein expression 
(values expressed relative to control; n=4-5/group). Insulin stimulates C) GLUT4 and D) 
GLUT8 trafficking to the atrial cell surface in type 1 diabetic (T1 Dx) subjects. Top 
panels: representative Western blot. Bottom panels: Mean ± SE of cell surface GLUT 
protein content (values expressed relative to control basal labeled; n=4-6/group). Methods: 
Intact mouse hearts were perfused with and without insulin, and photolabeled with bio-
LC-ATB-BGPA to determine the amount of cell surface (L: labeled fraction) and 
intracellular (UL: unlabeled fraction) content. T1Dx: type 1 diabetic; * P<0.05 vs. control; 





Although the heart is one of the main organs to utilize glucose as a metabolic 
substrate, very little is known about atrial glucose metabolism in both healthy and 
diseased conditions. Our data demonstrates that 1) a regional heterogeneity exists 
between GLUT4 and 8 expression in atria vs. ventricle; 2) both GLUT-4 and -8 are 
insulin-sensitive in the healthy atria; 3) diabetes impaired GLUT-4 and -8 trafficking to 
the atrial cell surface; and 4) insulin stimulation rescued GLUT translocation to the atrial 
cell surface during type 1 diabetes. 
In order to sustain its high energy demand, the rate of glucose utilization in the 
heart is greater than in skeletal muscle, adipose tissue and lung, despite the ability of the 
myocardium to use other substrates (i.e., fatty acids, lactate, ketone bodies and amino 
acids) 
20
. Glucose entry from the blood stream into the cell is the rate-limiting step in 
glucose utilization and occurs primarily via a group of facilitative glucose transporters 
(GLUT) 
289
. Despite the crucial role of the atria as a pacemaker of the heart, studies on 
the role of glucose transport and utilization in the atria have been scarce. The majority of 
the studies that have investigated cardiac energetics have studied the global or left 
ventricular changes 
32-37
. Due to the relatively small size of atria, specifically in rodent 
models (i.e., <30 mg), it is difficult to study membrane trafficking of GLUTs and, to our 
knowledge, we are the first to apply the biotinylation assay technique to the study of 
GLUTs in the atria. Please note that we previously reported that GLUT trafficking upon 
insulin stimulation is comparable between isolated rat ventricular myocytes and intact 
mouse ventricle 
295
. Using the photolabeled technique in the intact perfused mouse heart, 
we demonstrated that GLUT4 translocated to the atrial cell surface upon insulin 
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stimulation, similar to findings reported in the ventricle 
37;295
. We further observed in the 
current study a greater active cell surface GLUT4 content in the healthy atria compared to 
the ventricle under basal and insulin stimulated conditions. The finding of this study is 
concurrent with Ware et al. 
294
, which demonstrated regional pattern of total GLUT4 
content in the chambers of the healthy myocardium. The mechanisms underlying this 
regional heterogeneity are not well elucidated. In order to sustain the faster contraction 
rate, atrial myocytes possess unique electrophysiological properties, including faster 
calcium release from the sarcoplasmic reticulum (SR), greater inositol 1,4,5-trisphosphate 
(IP3) content and greater calcium buffering abilities 
302
. Since SR calcium handling 
regulates GLUT4 trafficking to cell surface in the myocardium,
295
 one could speculate 
that these well-known differences in calcium homeostasis could explain the greater cell 
surface GLUT4 expression in the atria compared to the ventricle. This regional 
heterogeneity further underscores the importance to specifically study glucose 
metabolism in the tissue of interest and the fact that one cannot extrapolate findings from 
the ventricle to the atria. 
Class I transporter GLUT4, the most extensively studied insulin-sensitive GLUT, 
is predominantly expressed in the adult heart (~70% of total myocardium GLUTs) and is 
thought to be responsible for insulin-stimulated glucose uptake 
24
. However, in a study 
conducted by Katz et al., it has been reported that GLUT4 null mice do not develop 
hyperglycemia, suggesting that other GLUT isoforms could be involved in the regulation 
of whole-body glucose homeostasis 
25
. GLUT8, one of the most recently discovered 
GLUT isoforms and member of the lesser known Class III, has been shown to be present 





. However, whether or not GLUT8 is primarily located at the cell 
surface or in intracellular compartment is unclear. Although GLUT8 has been reported to 
be an insulin-dependent isoform in blastocysts and hepatocytes 
30;31
, its role in the heart 
has not been determined.  Similar to GLUT4, our data demonstrated that GLUT8 
translocates from an intracellular pool to the cell surface of the healthy myocardium upon 
insulin stimulation using the biotinylation assay. In addition, our findings also 
demonstrate that similar to GLUT4, GLUT8 is mostly intracellular under basal condition. 
This is in agreement with previous studies that reported that GLUT8 carries a NH2-
terminal di-leucine motif that directs the protein to an intracellular localization and has 
the potential to translocate to the plasma membrane 
237
. Collectively, these data suggest 
that GLUT8 is a novel insulin-sensitive GLUT in the heart. In addition, in the present 
study, insulin stimulation increased GLUT8 translocation to the cell surface in the atria to a 
greater extent than in the ventricle, suggesting that GLUT8 primarily contributes to insulin-
stimulated glucose uptake in the atria. Due to the diversity of the insulin-sensitive 
GLUTs, characterization of the relative abundance and role of these novel GLUT 
isoforms (primarily from the Class III) in the heart is an important step towards 
understanding how these GLUTs contribute towards maintaining myocardial glucose 
transport.  
 In all the insulin-sensitive tissues (i.e., striated muscle and adipose tissue), insulin 
signaling via PI3K/Akt pathways plays a key role in cardiac glucose uptake.  As insulin 
binds to its receptor, the downstream insulin signaling pathway is activated, resulting in 
the phosphorylation of protein kinase Akt at threonine 308 (Th308) residues, which is 
located in the kinase domain of the Akt activation loop. The full activation of Akt 
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requires a further phosphorylation of serine 473 (s473) residues 
268;269
. It is well 
documented that the phosphorylation of both sites (s473 and Th308) are crucial for 
GLUT trafficking. The activated Akt in turn phosphorylates AS160, which is the most 
distal signaling protein that has been implicated in insulin mediated GLUT translocation 
and has emerged as a key regulator of GLUT trafficking 
271
. Under basal conditions, 
AS160 retains GLUT vesicles at the intracellular inactive pool 
269
. The phosphorylation 
of AS160 allows the activation of RabGTP, which initiates the signal transduction 
pathway that is necessary for the docking and diffusion of GLUT vesicles on the plasma 
membrane 
271
. It is important to note that, the initiation of the signaling cascade by the 
activation of the insulin receptor not only increases GLUT4 exocytosis at the membrane, 
it also attenuates GLUT4 endocytosis causing an enhanced re-distribution of GLUT4 
protein at the plasma membrane, facilitating cellular glucose uptake 
270
. Although this 
pathway has been well investigated in skeletal muscle and adipose tissue, the downstream 
signaling pathway that regulates glucose transport in the atria remains to be 
characterized. Our findings indicated that insulin stimulation increased the 
phosphorylation of Akt (at both s473 and Th308 sites) and AS160 in cardiac myocytes. 
We also demonstrated that the activation of downstream insulin signaling pathway was 
significantly correlated to the increased GLUT-4 and -8 protein expression in the atria. 
Due to the small size of the rodent atria, both membrane trafficking experiments and 
quantification of cytosolic proteins were not technically possible to perform in the same 
sample. Nonetheless, findings from this study provide novel insights in understanding the 
regulation of the insulin-sensitive GLUT isoform in the atria. In addition to Akt 
activating GLUT trafficking, there is an increasing evidence that Rac1 activation is 
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essential for GLUT4 trafficking to the cell surface and insulin-stimulated glucose uptake 
in skeletal muscle 
303-307
. In addition, Akt-independent signaling pathway through TUG 
(tether containing a UBX domain for GLUT4) has been reported to be essential in 
maintaining protein stability and trapping the GLUT4 containing storage vesicles in the 
Golgi matrix in skeletal muscle and adipose tissue 
308-311
. Although cardiac GLUT 
trafficking may be regulated by similar Akt-dependent and Akt-independent pathways, 
additional studies are required to fully characterize the regulation of GLUT trafficking in 
the myocardium, including in the atria.  
STZ administration destroys the beta cell of the pancreas and induces a 
hyperglycemic state. As such, it is a well-established experimental model of insulin-
deficient (type 1) diabetes 
37;295;296
. Although alterations of metabolic efficiency have 
been described in the ventricle of this animal model 
37;251;295;296
, whether diabetes induces 
alterations in glucose metabolism in the diabetic atria is unknown. Our data demonstrated 
a decrease in total GLUT-4 and -8 protein content in the atria of STZ-induced diabetic 
animals. Further, using the biotinylated photolabeled assay, our data demonstrated a 70% 
and 88% decrease in cell surface GLUT-4 and -8 protein content in the diabetic atria, 
respectively. This finding is consistent with the previous studies that reported impaired 
GLUT4 translocation in the ventricle of type 1 diabetic rats 
251
. In addition, the role and 
regulation of GLUT8 during insulin-deficient diabetic conditions have received scarce 
attention. Gorovits et al. reported that short-term STZ-induced diabetes significantly 
decreased GLUT8 mRNA levels in the liver and suggested that GLUT8 contributes to 
glucose homeostasis 
30
. Similar quantification of GLUT mRNA expression in the atria 
could be an avenue for future investigations. In another study, Piroli et al. reported the 
68 
 
alteration of protein expression and disruption of subcellular distribution of GLUT8 in 
the hippocampus of the type 1 diabetic rat 
263;264
. However, to our knowledge, there is no 
study that has investigated the regulation of GLUT8 in the cardiac tissue, more 
specifically in the atria.  Our findings demonstrate that diabetes induces an impairment in 
GLUT8 trafficking to the cell surface of the atria.  
We further investigated whether the down-regulation of cell surface GLUT-4 and 
-8 protein expressions was attributed to a defective insulin signaling pathway and/or due 
to a lack of insulin production in the atria of type 1 diabetic subjects. We reported no 
significant impairment in the phosphorylation of Akt (both s473 and Th308) and AS160, 
suggesting that the downstream insulin signaling pathway is not altered. This finding is 
consistent with a study by Laviola and colleagues, who reported that there was no 
significant decrease in the phosphorylation of Akt at s473 and Th308 sites in the ventricle 
of STZ induced diabetic rats compared to controls 
278
. To further confirm these findings, 
we stimulated the diabetic atria with and without insulin (at physiological concentration), 
and our results demonstrated that insulin stimulation rescued cell surface GLUT4 and 8 
protein expression in the diabetic atria, suggesting that the down-regulation of both 
insulin-sensitive GLUTs was mostly attributed to the lack of insulin production 
(following beta cell destruction) rather than an existing defect in the insulin signaling 
pathway in the atria of type 1 diabetic animals. 
CONCLUSIONS 
Using a cell surface biotinylation assay, we demonstrated that the major GLUT isoform, 
GLUT4, and the novel GLUT8 isoform are both insulin-sensitive transporters. Our data 
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further suggested that GLUT translocation to the cell surface is modulated by the 
downstream insulin signaling pathway via Akt and/or AS160 phosphorylation. We 
further demonstrated that diabetes impairs the trafficking of both GLUT-4 and -8, which 
was rescued by insulin stimulation in the diabetic atria. These alterations in atrial glucose 
transport may induce perturbations in energy production and could provide a metabolic 
substrate for atrial fibrillation, the most common abnormal heart rhythm in the world. 
Therefore, better understanding of the regulation of glucose transport may lead to the 
discovery of novel therapeutic targets for the treatment of cardiovascular complications 
associated with diabetes, including atrial fibrillation. 
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THE REGULATION OF THE INSULIN-SENSITIVE GLUCOSE TRANSPORTERS 







Diabetes and obesity have been identified as major risk factors for atrial 
fibrillation (AF). However, whether a metabolic substrate underlies AF is unknown. 
Glucose transport into the cell via Glucose Transporters (GLUTs) is the rate-limiting step 
of glucose utilization. Although GLUT4 is the major isoform in the heart, GLUT8 has 
recently emerged as a novel cardiac isoform. However, its role in the heart is not well 
known. We hypothesized that GLUT-4 and -8 translocation to the atrial cell surface will 
be impaired during insulin- resistance-induced AF. AF was induced by transesophageal 
atrial pacing in healthy and long-term high-fat-diet (HFD)-induced insulin-resistant (IR) 
mice. Expression of GLUTs and key proteins involved in the insulin signaling pathway 
was measured by Western blot in atrial tissue. Active cell surface GLUT content was 
measured using the state-of-the-art biotinylated photolabeled assay in the perfused heart. 
After 6 months on a HFD, mice were obese and hyperglycemic, and developed insulin 
resistance compared to mice on a control diet. IR animals demonstrated an increased 
susceptibility and propensity for AF. In the IR atria, active cell surface and total GLUT4 
content was down-regulated (by 66% and 40%, respectively, P<0.05) under basal 
condition. Long-term HFD-induced IR resulted in impairment in Akt and AS160 
phosphorylation, which was significantly correlated with GLUT4 protein content in the 
atria. These data suggest an impairment of the insulin signaling pathway, which was 
further confirmed by altered trafficking of both GLUT-4 and -8 to the cell surface upon 
insulin stimulation in the IR atria. In conclusion, our data suggest that: 1) IR increases the 
vulnerability to AF; 2) GLUT-4 and -8 trafficking is altered in the IR atria due to 
impairments in the insulin signaling pathway. Therefore, alterations in atrial glucose 
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transport may induce perturbations in energy production and could provide a metabolic 
substrate for atrial fibrillation during insulin-resistance and obesity. 
INTRODUCTION 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the world, 
affecting 2% of the entire world population, and has been identified as an increasing 
public health risk as well.
7
 AF considerably increases the risk factors for heart failure, 
ischemic heart disease and stroke.
7-10
 Although AF is thought to be multifactorial and its 
pathogenesis remains elusive, recent epidemiological studies have identified type 2 
diabetes and obesity as major and independent risk factors of AF.
15;19;185;186;189;190;312-315
 
Meta-analysis studies have reported that diabetic and obese populations have increased 
risk of AF by 40% and 49% respectively.
184;316
 
Diabetes mellitus is a global epidemic health problem currently affecting 
approximately 30 million people in the US.
1
 Non-insulin-dependent type 2 diabetes 
affects approximately 90% of the total diabetic population. Type 2 diabetes significantly 
increases the risk factors for various cardiac complications including myocardial 
infarction and AF. Importantly, it has been reported that cardiac complications occur 
even in the pre-diabetic state (marked by glucose intolerance, normal glycemia to mild 
hyperglycemia and insulin resistance), which poses a significant medical and economic 
burden on the society.
317-320
 According to the American Diabetes Association, 37% of 
American adults over the age of 20 suffer from pre-diabetes.
321
 In addition, reports from 
prospective clinical studies state that each year approximately 11% of the pre-diabetic 
population progress to type 2 diabetes.
321
 Results from meta-analysis studies suggest that 
pre-diabetic patients have 1.5 folds increased risk of cardiovascular diseases compared to 
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2-4 folds increased in risk in diabetes patients.
322;323
 Although the risk factor of a diabetic 
patient to develop AF is 1.4-2.2 compared to a healthy non-diabetic person,
185;189;190;312;318
 
the underlying pathophysiologic mechanisms linking diabetes and AF are not well 
understood. Insulin resistance and hyperglycemia are the hallmark of type 2 diabetes, 
caused by a lack of insulin action in the insulin-sensitive tissues (skeletal muscle, adipose 
tissue and the heart) resulting in dysfunctional glucose uptake.
4;113;324;325
 Interestingly, 
insulin resistance has also been reported to be more prominent in patients with AF 
compared to those with sinus rhythm.
19
 Insulin resistance coupled with inadequate 
glycemic control during diabetes has often been associated with AF episodes.
5;13;17;19
 In 
addition, AF attacks in non-insulin-dependent type 2 diabetes patient have been reported 
to be preceded by hyperglycemic states.
16
 Together the results of all these studies suggest 
a strong correlation of insulin resistance and an inadequate glycemic control with AF. 
Since the rate of glucose uptake and utilization in the heart is higher than any other tissue, 
dysfunctional glucose uptake (i.e., lack of energy substrate) in the cardiac tissue, 
specifically the atria (containing the pacemaker of the heart) could be a major 




  Glucose transport from the blood stream into the cell is conducted by a facilitative 
diffusion process involving a specialized family of Glucose Transporters (GLUTs) and is 
the rate limiting step of glucose utilization.
289
 Although they are many isoforms, GLUT4 
and GLUT8 have been identified as the major insulin sensitive isoforms in healthy 
cardiac tissue.
27;29-31;326
 However, the expression and regulation of these isoforms in the 
heart during insulin resistant type 2 diabetes remain unclear. In adipocytes, it has been 
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reported that there is a substantial down regulation of GLUT4 protein and mRNA levels 
during type 2 diabetes and obesity.
252;253 
In the skeletal muscle, no change in the total 
level of GLUT4 has been reported between type 2 diabetic and non-diabetic 
patients.
252;256;257;260;327;328
 Although the level of GLUT4 was unchanged in skeletal 
muscle, impairment in GLUT4 vesicular trafficking has been reported in these 
tissues.
243;260
 In contrast to the extensive research carried out on GLUT4, the role of 
GLUT8 in many tissues still needs to be investigated. Gorovits et al. reported that 
GLUT8 mRNA decreased during hypoinsulinemia and increased during 
hyperinsulinemia in the liver, suggesting a regulatory role of insulin in GLUT8 mRNA 
expression.
30
 To the best of our knowledge, there has been no study that investigates the 
regulation and expression of these GLUT isoforms in the atria and in the context of 
insulin resistance and AF.    
Although insulin-resistant type 2 diabetic patients have an increased risk to 
develop AF, no causal link has been established between these 2 insidious conditions. 
Therefore, in this study, we hypothesized that 1) mice fed a high-fat-diet will be more 
vulnerable to AF induction with higher propensity to AF and 2) GLUT trafficking and its 
downstream insulin signaling pathway will be impaired in the atria of insulin resistant 
mice. Our goal is to determine whether alterations in atrial glucose transport could 






MATERIALS AND METHOD 
Insulin-Resistant Animals 
Five-week-old C57BL/6 male mice (Charles River Laboratories) were used. After a one-
week acclimatization period, mice were fed either a control diet (9.4% kcal from fat - 
soybean oil, 14.7% kcal protein and 75.9% kcal from carbohydrate; AIN-93M) or a high-
fat diet (60% kcal from fat (soybean oil and lard), 20% kcal protein and 20% kcal from 
carbohydrate; Research Diets, Inc.; D12492) for 24 weeks. Both diets had comparable 
amounts of vitamin and minerals. Body weights and blood glucose levels were recorded 
every 4 weeks throughout the experimental period. At 24 weeks, the mice were 
anesthetized using 3% isoflurane and euthanized by excision of the heart followed by 
either flash freezing the heart in liquid N2 or Langendorff perfusion. Due to experimental 
constraints, few of the control animals were of age matched FVB/N strain. All procedures 
were approved by the Oklahoma State University Institutional Animal Care and Use 
Committee.  
Blood Chemistry 
 After 8 hours of fasting, blood glucose was measured using a handheld 
glucometer (Bayer Contour, Tarrytown, NY). Venous blood was collected by lancing the 
facial vein.  At the end of the study period (24 weeks) fasting serum insulin was 
measured using commercially available sandwich ELISAs (Serum Insulin ELISA kit, 




Intraperitoneal Glucose Tolerance Test 
At 24 weeks, an intraperitoneal glucose tolerance test was performed. Following a 
8 hour fast, non-sedated mice received 1.5 g/kg glucose bolus intraperitoneally and blood 
glucose concentrations were measured at time points from 0, 15, 30, 45, 60 and 120 min. 
Changes in blood glucose was determined by calculating the area under the curve (AUC). 
Lower AUC values reflect more efficient glucose clearance.  
Intraperitoneal Insulin Tolerance Test 
At 24 weeks, an intraperitoneal insulin tolerance test was performed. Following a 
8 hour fast, non-sedated mice received 0.75 U/kg insulin (Novolin, Novonordisk) bolus 
intraperitoneally and blood glucose concentrations were measured at time points from 0, 
15, 30, 45, 60 and 120 min. Changes in blood glucose was determined by calculating the 
area under the curve (AUC). Lower AUC values reflect more efficient glucose clearance.  
Atrial Fibrillation Induction 
All of the mice were fully electrophysiologically examined by closed chest 
transesophageal recording and atrial stimulation under anesthesia (ketamine/xylazine IP 
injection). A 2.2 Fr 6-polar catheter was inserted through the esophagus and positioned 
near the left atrium. Positioning of the appropriate bipolar pair of electrodes adjacent to 
the left atrium was accomplished by sequentially connecting each bipolar pair to an 
iPhone in the AliveCor application mode. An iPhone with the AliveCor application was 
also used to record the body surface ECG by inserting two metal pins under the mouse’s 
skin. Heart rate and body temperature was recorded during the entire procedure for all of 
the animals. The current, in milliamperes, was determined by connecting the terminals of 
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the predetermined pairs of electrodes to the battery powered (DC) stimulator (each pulse 
duration = 1millisecond), which provided pace capture of the atrium. This threshold was 
recorded and increased by 2X to ensure constant atrial pacing at a rate faster than the 
baseline rate. By switching the same terminals to the AC-powered stimulator the atrial 
pacing threshold (in volts) was determined. This voltage threshold was recorded and at 
2X threshold constant atrial pacing was achieved and noted. In order to induce atrial 
fibrillation (AF), the same site was subjected to burst pacing for 10 seconds at 2 different 
frequencies - 20 Hz (1200/min)  and 40 Hz (2400/min) - twice. The same protocol was 
applied for both the control and the IR animals.  
Duration (in seconds), frequency (number of incidences per animal)  of atrial 
fibrillation (defined as an absence of a defined P-waves and presence of irregularly 
irregular R-R interval), atrial tachycardia (increased heart rate without the defined P 
wave) and sick sinus syndrome (intermittent tachycardia and sinus bradycardia) were 
recorded after each burst pacing from the surface ECG traces. The total duration and 
frequencies of the atrial arrhythmias were recorded.  
Protein Extraction  
Total and crude extracts of membrane-enriched protein lysates of atrial 
myocardium were prepared as previously described.
37;295-297
 Briefly, total protein lysates 
from fresh atrial tissue were collected by incubating the tissue with lysis buffer (RIPA, 
Thermo fisher Scientific). Samples were centrifuged at 3000 g for 25 min, and the 
supernatant was stored at − 80 °C until further analysis. Crude membrane protein extracts 
were collected from frozen tissue samples that were homogenized in buffer containing 
78 
 
(mM): sucrose 210, NaCl 40, EDTA 2, HEPES 30, and protease inhibitor (Sigma, St. 
Louis, MO). The homogenate was incubated with sodium pyrophosphate 58 mM and KCl 
1.17 mM. Crude membranes were then recovered by centrifugation at 100,000 g for 90 
min at 4°C. Pellets were re-suspended with a cell lysis buffer (RIPA, Thermofisher 
Scientific). Samples were centrifuged at 3000 g for 25 min, and the supernatant was 
stored at − 80 °C until further analysis. 
Western Immunoblotting 
Equal amounts of protein (5-20 μg) were resolved in an 8-12% SDS-
polyacrylamide gel and electrophoretically transferred (BioRad) to a polyvinyl-idine 
fluoride membrane (Biorad), as previously described.
37;294-297;299;300
 After blocking (1-5% 
non-fat dry milk or 2% goat serum albumin), membranes were incubated with optimally 
diluted primary antibodies overnight (polyclonal rabbit anti-human GLUT4, 1:750, AbD 
Serotec 4670-1704; polyclonal rabbit anti-human GLUT8, 1:500, Bioss bs-4241R; 
monoclonal rabbit anti-mouse total Akt, 1:1000, Cell Signaling 4061; monoclonal rabbit 
anti-human phosphorylated Akt s473, 1:1000, Cell Signaling 4060; monoclonal rabbit 
anti-mouse phosphorylated Akt Th308, 1:1000, Cell Signaling 2965; monoclonal rabbit 
anti-human total AS160, 1:1000, Cell Signaling 2670 and polyclonal rabbit anti-human 
phosphorylated AS160, 1:1000, Cell Signaling 9611) followed by a 1 hour incubation of 
appropriate secondary antibodies conjugated to horseradish peroxidase (for total and 
phosphorylated Akt and AS160, Cell Signaling 7074, 1:2000, polyclonal goat anti-rabbit; 
for others, GE Healthcare NA934V, polyclonal donkey anti-rabbit). Primary antibodies 
were chosen based on their 100% sequence homology with the protein of interest in 
rodents, and validated against a positive control (i.e., tissue, peptide). Antibody-bound 
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transporter proteins were quantified by enhanced chemiluminescence reaction (KPL) and 
autoradiography. Band density and molecular weight were quantified using Gel Pro 
Analyzer (Media Cybernetics). The data was expressed relative to appropriate controls. 
Equal protein loading was confirmed by reprobing each membrane with Calsequestrin 
monoclonal IgG (Thermo-Scientific PA1-903, 1:2500, polyclonal rabbit anti-dog).  
Quantification of GLUT Translocation to the Cell Surface 
Following a 1 hour Langendorff perfusion (with and without 0.7 nm insulin), both 
healthy and insulin-resistant (IR) atrium were photolabeled with the cell surface 
impermeant biotinylated bis-glucose photolabeling reagent (bio-LC-ATB-BGPA, 300 
μM, Toronto Research Chemicals), of which the hexose group interacts specifically with 
the extracellular binding site of GLUTs. The photolabeled reagent was infused into the 
intact heart through the aorta before cross-linkage to cell surface GLUTs using a Rayonet 
photochemical reactor (340 nm, Southern New England UV), as previously 
described.
37;295;301
 Protein extraction was immediately followed with homogenization and 
ultracentrifugation (227,000 g, 50 min at 4°C). Recovery of photolabeled (cell surface) 
GLUTs from total cardiac membranes (200 μg) was achieved using streptavidin isolation 
(bound to 6% agarose beads) to facilitate separation of non-cell surface GLUTs 
("unlabeled" or intracellular fraction that remains in the supernatant) from cell surface 
GLUTs ("labeled" or sarcolemmal fraction). The labeled GLUTs were then dissociated 
from the streptavidin by boiling in Laemmli buffer for 30 min prior to SDS-PAGE and 
subsequent immunoblotting with GLUT antibody. Proteins from the labeled fraction were 
quantified by densitometry relative to the positive control, as previously 
described.
42;43;46;47




Number of animals: Power calculation for minimum sample size required was conducted 
using a statistical power of 0.5 and an alpha level of 0.1 to detect a 10% difference 
between groups with SigmaStat software 3.5 (Systat).  
Data Analysis: Normality and homogeneity of data were tested using Shapiro-wilk and 
Levene test, respectively. Differences between means were assessed using Student’s t-
tests, one or two-way analysis of variance (treatment and tissue) for in vitro 
measurements, as appropriate. Repeated measured 2-way ANOVA was performed for the 
in vivo measurements, with Student Newman Keuls post-hoc test. If not normally 
distributed, the data was analyzed with a Mann-Whitney or Friedman test. Linear 
correlations were performed using linear regression. Statistical significance was defined 
as P<0.05. Data are presented as mean ± SE. 
RESULTS 
Validation of the Animal Model 
We first confirmed obesity, hyperglycemia, hyperinsulinemia and impaired 
glucose tolerance in the high-fat diet-induced insulin-resistant (IR) animals. The animals 
that were fed a high fat diet quickly gained weight compared to the control animals (Fig 
1A) and the obesity persisted through the end of the study (24 weeks). At the end of the 
24 week period, the high-fat diet-fed mice gained 150% of their initial body weight 
compared to control mice which gained only 40% (P < 0.05, Fig 1A). Within 12 weeks, 
the IR animals developed mild hyperglycemia in contrast to their control counterparts (P 
< 0.05, Fig 1B). At 24 weeks, glucose and insulin tolerance tests (IPGTT and IPITT 
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respectively) were performed on animals following fasting for 8h. All the mice fed the 
high-fat diet developed impaired glucose and insulin tolerance (P < 0.05, Fig 1 C/D, 
IPGTT  and 1 E/F, IPITT) compared to their normal-diet-fed control counterparts. In 
addition, the high-fat-diet-fed animals had approximately fivefold higher fasting serum 
insulin level compared to the control animals (P < 0.05, Fig 1G). Therefore, by the end of 
the 24 week study period, the high-fat diet-fed animals were obese, mildly hyperglycemic 
(blood glucose level of 217±52 mg/dL), hyperinsulinemic and developed impaired 
glucose tolerance. With these findings we confirmed insulin resistance in our high-fat-
































Figure 1: Validation of the insulin-resistant animal model 
Higher A) Mean ± SE Body Weight and B) Mean ± SE venous blood glucose 
concentration obtained at baseline and up to 24 weeks  after induction of insulin-resistance (IR) 
(n=10-15 mice/group); # P<0.05 vs. Control; * P<0.05 vs. Baseline (0 weeks) C) Impaired 
Intraperitoneal glucose tolerance (IPGTT) of IR animals (n=15-16 mice/group); # P<0.05 
vs. Control; * P<0.05 vs. Baseline (0 weeks) D) AUC = area under the curve for [glucose] 
measured during IPGTT. (n=15-16 mice/group); # P<0.05 vs. Control F) Impaired 
Intraperitoneal Insulin tolerance (IPITT) of IR animals (n=7 mice/group); # P<0.05 vs. 
Control; * P<0.05 vs. Baseline (0 weeks) D) AUC = area under the curve for [glucose] 
measured during IPITT. (n=7 mice/group); # P<0.05 vs. Control G) Hyperinsulinemia 
observed in IR animals. Fasted serum insulin levels measured at 24 weeks of high-fat diet. 




Increased vulnerability of insulin resistant subjects towards AF induction 
In order to investigate the vulnerability of our animal model to the induction of 
AF, we paced the atria with a total of 4 consecutive 10 second bursts of 20Hz (1200/min) 
(2 bursts) and 40Hz (2400/min) (2 bursts). Our results indicated longer duration and 
greater frequency of atrial arrhythmia in all the insulin-resistant (IR) animals (P < 0.05, 
Fig 2). We first quantified the average duration (Fig 2A) and frequency (Fig 2B) of all 
the observed atrial tachy-arrhythmias, including atrial fibrillation, atrial tachycardia and 
sick sinus syndrome. Our results indicated an 8 times greater average duration and 6 
times greater frequency of atrial arrhythmia in the IR animals compared to the controls. It 
is important to note that, all of the diabetic atria were susceptible to some or all forms of 
atrial tachyarrhythmia (Fig 2C/D). Importantly, atrial fibrillation was observed in all of 
the IR animals (7 out of 7) with the total duration ranging from 9-43 seconds (Fig 2C/D). 



























Figure 2: Longer duration and greater frequency of atrial tachy-arrhythmia and 
atrial fibrillation in the insulin-resistant animals 
  (A) Longer duration and (B) greater frequency of combined atrial arrhythmia in 
the insulin-resistant (IR) animals (n=4-7 mice/group); # P<0.05 vs. Control; Top 
panels: Representative ECG Traces.  (C) Longer duration and (D) greater 
frequency of atrial fibrillation in the IR animals (n=4-7 mice/group); # P<0.05 vs. 
Control. Atrial arrhythmia: Includes atrial fibrillation, atrial tachycardia and sick sinus 
syndrome. Frequency: Average of the total incidence of atrial arrhythmia/atrial 




Impaired GLUT trafficking in the atria of the insulin-resistant animals 
After we had established the increased vulnerability to AF in the insulin-resistant 
(IR) animals, we further investigated the alterations in the atrial glucose transport by 
quantifying the expression and regulation of the major GLUT isoforms (GLUT-4 and -8). 
We first measured the total GLUT-4 and -8 protein expressions in the atria of healthy and 
IR mice (Fig 3 A/B). Our results indicated a significant decrease by 38% in total GLUT4 
protein expression in the atrial tissue during IR compared to control (P < 0.05, Fig 3A). 
However, there were no significant changes in GLUT8 total protein expression (Fig 4B). 
To accurately differentiate plasma membrane-associated GLUTs (labeled fraction) from 
intracellular GLUT (unlabeled fraction), we used the biotinylated assay in the intact 
perfused atria of control and IR animals (Fig 3 C/D/E/F). Under basal conditions, we 
observed a significant down-regulation of atrial cell surface GLUT4 by 66%, in the IR 
atria compared to healthy controls (P < 0.05, Fig 3C/E). However, our results did not 
indicate any alteration in cell surface GLUT8 expression in the IR atria (Fig 3D/F). We 
further compared the cell surface fraction of both GLUTs (4 and 8) to the intracellular 
fractions in both the healthy and IR animals (Fig 3C/D). As expected both the isoforms 
were mostly intracellular under basal conditions. Cell surface fraction of GLUT4 was 
27% and 13% of the intracellular fraction in the healthy and IR animals, respectively. 
Similarly, under basal conditions, GLUT8 cell surface fraction was 7% and 6.5% in the 
healthy and IR animals respectively (Fig 3C/D).  
In order to investigate alterations in GLUT trafficking during IR, cell surface 
GLUT trafficking was measured using the biotinylated assay in the intact perfused atria 
after in vitro insulin stimulation (Fig 3 E/F). We have previously described that both 
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GLUT-4 and -8 are insulin sensitive in the healthy atria.
326
 Therefore, as expected in the 
healthy animals, we observed a significant increase in cell surface GLUT-4 and -8 
expressions (by 250% and 500% respectively) upon insulin stimulation. In contrast, 
insulin –induced GLUT (-4 and -8) translocation to the atrial cell surface was impaired in 
the atria of IR mice. Although we did not observe any alterations in total GLUT8 
expression in the IR animals, our results indicated an impairment in GLUT8 trafficking to 
the atrial cell surface. Therefore, we speculated that cardiac insulin resistance caused 































Figure 3: Alteration in the trafficking of the insulin-sensitive GLUTs in the atria 
of the insulin-resistant animals 
Total expression of A) GLUT4 and B) GLUT8 during insulin-resistance (IR) vs. 
healthy (Control). Top panels: representative Western blot. Calsequestrin (CLSQ) was 
used as a loading control. Bottom Panels: Mean ± SE of Total GLUT protein content, 
normalized to control (n=6/group). Majority of C) GLUT4 and D) GLUT8 is 
intracellular under basal conditions (n=4/group). Methods: Cell surface GLUT 
measured using biotinylated photolabeling technique in intact perfused mouse heart. L: 
Labeled (cell surface fraction); UL: Unlabeled (intracellular fraction). # P<0.05 vs. 
control. Insulin stimulates E) GLUT4 and F) GLUT8 trafficking to the healthy but not 
IR atrial cell surface in the intact perfused mouse heart. Top panels: representative 
Western blot. Bottom Panels: Mean ± SE of cell surface GLUT protein content; values 
normalized to basal (n=4/group); # P<0.05 vs. basal; * P<0.05 vs. Control; Methods: Cell 
surface GLUT measured using biotinylated photolabeling technique. L: Labeled (cell surface 
fraction); UL: Unlabeled (intracellular fraction). 
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Impaired activation of insulin signaling pathway during insulin-resistance 
Our next aim was to investigate whether or not the alterations in GLUT (-4 and -
8) trafficking was due to impairment in the activation of the downstream insulin signaling 
pathway. To this end, we measured (total and phosphorylated) Akt and AS160 protein 
expression, key regulators of GLUT vesicular trafficking, in the healthy and insulin-
resistant (IR) atria by Western blotting (Fig 4). Our results indicated a significant 
decrease in phosphorylated Akt expression, at both serine 473 and threonine 308 
phosphorylation sites in the IR atria (P<0.05, Fig 4A). In addition, there was decreased 
phosphorylation of AS160, the most downstream proteins in the insulin signaling 
pathway regulating GLUT trafficking (P<0.05, 4B). Moreover, we reported a positive 
linear correlation observed between the decreased phosphorylation of Akt and AS160 and 
total GLUT4 expression in both the healthy and IR atria (P<0.05, Fig 4 C/D). These 
results suggest that Akt and AS160 regulate GLUT expression and/or trafficking in the 
atrial tissue of healthy and IR subjects. In contrast, we did not observe any significant 
linear correlation between GLUT8 and phosphorylated Akt or AS160 (Fig 4 E/F), which 
suggests that, in addition to the downstream insulin signaling pathway, other insulin-

























Figure 4: Impaired activation of insulin signaling pathway during insulin 
resistance  
Insulin-resistance (IR) decreased A) Akt and B) AS160 phosphorylation in the 
atria. Top panels: representative Western blot of total lysate from atrial tissue; 
calsequestrin (CLSQ) was used as a loading control. Bottom Panels: Mean ± SE; values 
normalized to control (n=5-6/group). # P<0.05 vs. Control. C) Significant positive 
linear correlation between Akt phosphorylation and total GLUT4 expression in 
healthy and IR atria. Mean ± SE; values normalized to control (n=5-6/group).  D) 
Significant linear correlation between AS160 phosphorylation and total GLUT4 
and expression in the healthy atria. Linear Correlation between E) Akt and F) AS160 
phosphorylation and total GLUT8 protein expression.  Mean ± SE; values normalized 




Spontaneous Atrial Fibrillation in the insulin-resistant animals  
In order to further investigate whether the insulin-resistant (IR) animals develop 
spontaneous AF, we monitored the animals for an additional 8 weeks (totaling 32 weeks 
on high fat diet). Our results indicated 6 folds longer duration (Fig 5A) and 8 folds 
greater frequency (Fig 5B) of AF in the IR animals. However, because of some individual 
variations, we only reported a statistical trend. In addition, the cumulative duration and 
observations of AF was significantly higher in the IR compared to the control groups 
(74.9 s vs 21.6 s and 16 vs. 2, respectively; P<0.001, Fig 5C and D). These findings 































Figure 5: Spontaneous atrial fibrillation in the insulin-resistant animals 
 (A) Mean duration and (B) Frequency of Spontaneous Atrial Fibrillation in the 
insulin-resistant (IR) animals (n=13/group); (C) Cumulative Duration and (D) 
Cumulative Incident of Atrial Fibrillation in the IR animals. (n=13/group); #, P<0.001 
vs. Control; Frequency: Average of the total incidence of atrial fibrillation. Methods: 





Although type 2 diabetes and insulin resistance have been identified as an 
independent risk factors of atrial fibrillation, to the best of our knowledge, no study has 
established a causal link between insulin-resistance and atrial fibrillation. In this study, 
we demonstrated that 1) the insulin-resistant atria had an increased vulnerability and 
propensity to AF induction and 2) the insulin-resistant atria had impairment in trafficking 
of major cardiac isoform GLUT4 and novel isoform GLUT8 to the atrial cell surface, 
along with decreased activation of downstream insulin signaling pathway. 
Insulin-resistant type 2 diabetes has been reported to account for 90% of the entire 
diabetic population and, similar to AF, is more prevalent among adults. In the current 
study we have used long term (6 months) high-fat diet-fed mice as an insulin-resistant 
(IR) animal model, which is characterized by obesity, glucose intolerance, 
hyperinsulinemia and mild hyperglycemia.
329-333
  With the exception of mild 
hyperglycemia, these animals demonstrated the characteristics of type 2 diabetes and 
therefore can be considered to be in a ‘pre-diabetic’ state. However, since pre-diabetes 
has been recognized as an independent risk factor for diabetic cardiomyopathy, the IR 
animal model developed in the current study can be considered appropriate to investigate 
the underlying mechanisms of diabetes induced AF.
317-320
 
Due to the absence of an animal model of spontaneous AF, it has been difficult to 
characterize the underlying pathophysiological link between these two insidious diseases. 
The majority of the research in this area has been therefore conducted by inducing short 
term AF with transesophageal or trans-venous atrial pacing.
154;334-337
  The advantages of 
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using transesophageal stimulation is that it is minimally invasive, allows multiple 
examinations of the same animal with different experimental conditions and that it is free 
from the mechanical alterations of the atrial tissue which are associated with the more 
invasive open chest stimulations or catheterization.
334
 Due to the small size of the mouse 
atria, the propensity to generate re-entry circuits (which is crucial for the initiation of AF) 
in the mouse atrium is much less probable compared to a large animal model. However, 
by placing the lead directly adjacent to the left atrium, this technique allows successful 
atrial pacing in a small animal model. Therefore, in the current study we have used 
transesophageal atrial pacing to test the vulnerability of our animal model to AF 
induction. Our results indicated that hyperinsulinemic mice had greater frequency and 
longer duration of atrial tachy-arrhythmia, including atrial fibrillation, atrial tachycardia 
and sick sinus syndrome. Similarly Takahashi et al. reported increased atrial tachycardia 
in short term high-fat diet-fed mice during transvenous (jugular vein) atrial pacing, 
although they did not report the incidence of AF itself.
335
 In the current study, the 
duration and frequency of AF in the hyperinsulinemic animals was significantly longer 
compared to the healthy control animals. In a large animal model of long term high-fat 
diet, Abed et al. reported higher susceptibility to AF during open chest atrial pacing. 
However, none of these studies investigated the metabolic state of the animals and its 
relation to AF.
312
 Although Kato et al. reported higher arrhythmogenic factors in the 
excised perfused rat atria of genetic type 2 diabetic rat model, arrhythmia was induced ex 
vivo (intact perfused heart) by subjecting the left atrial appendage with to an 
extrastimulus.
14
 Finally, the occurrence of spontaneous AF in animal models with 





 meaning initial sporadic AF cause spontaneous series of structural and electrical 
remodeling that promote maintenance of persistent AF.
118;122
 In order to investigate 
whether our animal model will also develop spontaneous AF (in addition to atrial pacing-
induced AF), we recorded baseline ECGs after feeding a long term (i.e., 32 weeks) high fat 
diet. Interestingly, we observed significantly higher cumulative duration of AF in the IR 
animals compared to the control. In conclusion, we are the first to report a causal link 
between (induced and spontaneous) AF in an animal model of insulin resistance.  
Cellular insulin resistance in the insulin-sensitive tissue (skeletal muscle, adipose 
tissue and the heart) is the hallmark of type 2 diabetes. Interestingly, insulin resistance 
has been associated with atrial fibrillation. Ostgren et al., identified that a combination of 
insulin resistance and impaired glycemic control was more prominent in patients with AF 
compared to those with sinus rhythm.
19
 In another study, it was reported that high fasting 
blood glucose and insulin levels in diabetic patients were correlated with the risk factor 
for the development of AF. This risk factor increased with the duration and severity of 
diabetes.
15
 In addition, Dublin et al. reported that the risk of developing AF of a diabetic 
patient increases approximately 3% for each additional year of diabetes duration.
17
 
Another study by Rigalleau et al. reported that major hyperglycemic episodes precede AF 
attack in insulin-resistant type 2 diabetic patients.
16
 Together the results of all these 
studies
5 
suggest a strong correlation of insulin resistance and an irregular glycemic state 
with AF. In agreement with the above studies
17;19;185;189-192
  our findings also 




 In a recent study, we reported that the major cardiac isoform GLUT4 and novel 
isoform GLUT8 are insulin sensitive in the healthy atria.
326
 Therefore, in the current 
study we speculated that alterations in the expression and regulation of these major 
insulin-sensitive GLUT isoforms in the insulin resistant model could play a major role in 
the pathogenesis in the induction of atrial fibrillation. Although GLUT4 is the major 
insulin-sensitive glucose transporter in the heart, there have been very few studies that 
have investigated cardiac-specific alterations of GLUT4 during IR. Our results indicated 
a significant decrease in both total and active cell surface GLUT4 protein expression in 
the atria of IR compared to the control group under basal conditions. In contrast to 
GLUT4, the total protein and active cell surface expression of GLUT8 under basal 
conditions remained unchanged. However, when stimulated with insulin, there was a 
significantly impairment in trafficking of both insulin-sensitive GLUT8 and GLUT4 to 
the atrial cell surface, with indicated atrial insulin resistance. Similarly, decreased 
GLUT4 protein and mRNA levels have been reported in adipocytes during type 2 
diabetes.
253;293;338
 In skeletal muscle, no change in the total level of GLUT4 has been 
reported between insulin-resistant, diabetic and healthy patients. 
252;256;257;327;328
 However, 
significant impairment of insulin stimulated GLUT4 vesicular trafficking has been 
reported in patients with type 2 diabetes.
258-260
 It has been documented that, in skeletal 
muscle, insulin resistance alters sub-cellular localization of GLUT4 storage vesicles to 
dense membrane compartments from which insulin is unable to recruit GLUT to the cell 
surface.
260
   However, the regulation of glucose transport in the IR atria remains elusive. 
In contrast to GLUT4, there is a gap of knowledge regarding the molecular mechanisms 
regulating GLUT8 expression and translocation during insulin-resistance. Gorovits et al. 
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suggested a regulatory role of insulin on GLUT8 mRNA expression by showing a 
positive linear correlation between GLUT8 mRNA expression and circulating levels of 
plasma insulin in the liver.
30
 Similarly, previous findings from our laboratory reported 
significantly lower active GLUT8 expression in the atria of insulin-deficient diabetic 
animals.
326
 Adastra et al. suggested the involvement of GLUT8 in insulin resistance and 
obesity by reporting that, GLUT8 knock out mice are resistant to dietary-fat-induced 
weight gain and insulin resistance.
339
 In a similar study of a high fructose diet, DeBosch 
et al. suggested GLUT8 mediated deleterious metabolic effects such as decreased insulin 
sensitivity and glucose tolerance.
265
 However, the underlying mechanisms are still under 
debate. The results of the current study demonstrated the impaired trafficking of both 
insulin-sensitive GLUT-4 and -8 during IR, indicative of atrial insulin resistance.  
In order to investigate the mechanisms underlying the impaired trafficking of 
GLUT4 and GLUT8 to the atrial cell surface of the IR animals, we investigated the 
activation of downstream insulin signaling pathway by quantifying the phosphorylation 
of two key proteins Akt and AS160 by Western Blotting. It has been previously reported 
that in skeletal muscle and adipose tissue phosphorylation of Akt at th308 and s473 sites 
along with AS160 is essential in the vesicular trafficking of the intracellular GLUT4 
molecules.
242;243;245;247;249;268-271
  For instance, decreased Akt phosphorylation has been 
reported in skeletal muscle and adipose tissue of insulin resistant diabetic rats, genetically 
obese mice and biopsies of type 2 diabetic patients.
258;280-282;284;285
 In addition, Karlsson et 
al. found that impairment of insulin action on AS160 activation was associated with 
reduced phosphorylation of th308 in skeletal muscle of hyperinsulinemic subjects.
258
 
Alteration in GLUT4 translocation in the adipose tissue was also reported to be 
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associated with defective Akt phosphorylation.
285;286
 Similar to these findings, in the 
present study, we observed a significant decrease in phosphorylation of both Akt sites 
(th308 and s473) and AS160 in the atria of hyperinsulinemic animals compared to the 
healthy control group. In addition, we observed a significant linear positive correlation 
between Akt/AS160 activation and GLUT4 protein expression. One of the limitations of 
the current study is that due to the small size of the atria, analysis of downstream insulin 
signaling pathway and GLUT trafficking upon insulin stimulation was not quantifiable in 
the same atrial tissue (Fig 4). With the downregulation of Akt/AS160 activation under 
basal condition and impairment of insulin stimulated GLUT4/GLUT8 trafficking, the 
findings from the current study strongly indicate atrial/cardiac insulin resistance.  
In contrast to GLUT4, we did not observe any significant correlation between decreased 
Akt/AS160 activation with GLUT8 protein expression. Although in our previous study 
we reported a significant correlation with insulin stimulated AS160 phosphorylation and 
increased GLUT8 expression in healthy isolated atrial myocytes.
326
 Together, with these 
findings, it can be speculated that, in addition to the downstream insulin signaling 
pathway, other pathways regulate GLUT8 trafficking as well. Indeed, we previously 
reported that GLUT8 protein expression was positively correlated with pro-inflammatory 
cytokines IL-6 and SOCS3 in the ventricular tissue of mice fed a long-term high-fat diet, 
suggesting that cardiac inflammation could be a modulator of the novel GLUT8 
isoform.
340
 In addition, DeBosch et al. suggested that GLUT8 caused deleterious 
metabolic effects during high fructose diet.
265
 Their studies reported that GLUT8 
deficient mice were protected against  high-fructose-diet-induced fructose intolerance, 





  However, further studies are required to elucidate the role and regulation 
of GLUT8 during diabetes. 
CONCLUSIONS 
The heart is one of the main organs to utilize glucose as an energy substrate. 
Therefore, proper glucose uptake in the cardiac tissue is pivotal to proper cardiac 
function. Since the atria contains the pacemaker of the heart (the sinoatrial node), the 
availability of sufficient energy substrate (i.e., glucose) in the atria is essential. With the 
use of high-fat diet-induced insulin resistance and the state-of-the-art biotinylated 
photolabeled assay, we demonstrated an impairment in the trafficking of insulin-sensitive 
GLUT4 and GLUT8 (i.e., potential for dysfunctional glucose uptake) in the IR atria along 
with an impairment in the activation of downstream insulin signaling pathway, indicative 
of cardiac insulin resistance. In addition, we demonstrated that the insulin-resistant 
animals were highly vulnerable to AF and other atrial tachy-arrhythmias. Together, these 
findings suggest that alteration in the glucose transport in the insulin-resistant atria could 




















Diabetes has been identified as major independent risk factor for atrial fibrillation 
(AF).  However, the underlying pathophysiologic mechanisms of diabetes-induced AF 
are not well understood. Although recent studies suggest atrial fibrosis and advanced 
glycation end products (AGEs) as precursors, whether a metabolic substrate underlies AF 
remains unknown. It is possible that, in addition to structural remodeling, glucose and 
insulin disturbances during diabetes directly affect the function of the atrium, potentially 
leading to AF. We hypothesized that impaired glucose metabolism resulting from insulin 
dysregulation provides a metabolic substrate for the development and maintenance of 
atrial fibrillation. Transesophageal atrial pacing was used to induce AF in healthy, 
streptozotocin (STZ)-induced insulin-deficient (ID) and long-term high-fat-diet (HFD)-
induced insulin-resistant (IR) mice. The expression of pro-fibrotic markers Transforming 
Growth Factor β-1 (TGFβ-1) and Matrix Metallo-Proteinase-9 (MMP-9) were measured 
in the healthy and diseased atrium using Western blotting. Atrial fibrosis, advanced 
glycation end-products (AGE) and glycogen accumulation were measured using 
histological analysis.  The insulin-deficient (ID) and insulin-resistant (IR) subjects 
demonstrated an enhanced vulnerability and propensity to AF induction compared to the 
age-matched paired controls (P<0.05, respectively). In addition, we reported the absence 
of atrial fibrosis, glycogen and AGE accumulation in both groups with insulin 
dysregulation. Collectively, our data suggest that, in the absence of structural remodeling 
and atrial fibrosis, disturbances in the insulin and glycemic states were sufficient to 
increase the susceptibility towards AF.  Therefore, these data suggested that insulin 
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dysregulation leads to perturbations in energy production in the atria, which enhances its 
vulnerability to AF.                
INTRODUCTION 
Diabetes, a global epidemic health condition, currently affects 30 million people 
in the United States with approximately 1.5 million new cases every year. In the year 
2010, diabetes had been identified as 7
th
 leading cause of death in the US. Diabetes, 
characterized by chronic hyperglycemia, is either caused by lack of insulin production 
(type 1 diabetes) or the lack of insulin action/cellular insulin resistance (type 2 diabetes). 
It is well known that, diabetes significantly increases the risk factors for cardiovascular 
disease. The most common cardiac complications associated with diabetes are coronary 
artery disease, ischemic heart disease, diabetic cardiomyopathy and atrial fibrillation.
2
 
Atrial fibrillation (AF), the most common cardiac arrhythmia in the world, has been 
identified as an increasing public health problem as well.
5
 Approximately, 2% of the 
world’s population suffer from AF, and it is predicted that 16 million Americans will be 
affected by this insidious disease by the year 2050. In addition to worsening patient 
quality of life, AF is associated with stroke, heart failure and increased mortality. Recent 
epidemiological studies have identified diabetes as an independent risk factor for AF. The 
risk factor of a diabetic patient to develop AF has been reported to be 1.4-2.2 compared 
to a healthy non-diabetic person.
6;11-13;19
 However, the underlying pathophysiological 




  The development of AF is thought to be multifactorial, including 
structural and electrical remodeling, atrial fibrosis and dilation.
11;130
 It has been suggested 
that atrial fibrosis and AF occur in a concurrent manner, however whether or not there 
exists a direct cause and effect relationship remains elusive.
156
 The increased space 
between the cardiac myocytes due to the fibrotic deposit and expansion of extra cellular 
matrix can cause conduction delays and allow alternate pathways of conduction, thereby 
increasing the propensity of AF.
156;158
 Atrial fibrosis is difficult to reverse and therefore 
has been considered a major contributor in the progression from paroxysmal to persistent 
and eventually to permanent AF.
157
 
In addition to structural-electrical remodeling, glucose and insulin disturbances 
may also directly affect the function of the atrium potentially leading to AF.
13
 It has been 
reported that blood glucose level is significantly elevated during an AF attack.5 
15;16 It has 
also been reported that the risk of developing AF increases approximately 3% for each 
additional year of the duration of diabetes.
17
 In addition, increased accumulation of 
glycogen in the atrial tissue has been reported following 48 hours of rapid atrial pacing in 
a goat model, which eventually resulted in permanent AF. It was further reported that a 
greater glycogen accumulation occurred at the intercalated disc and at the myocyte 
junction in the left atrial appendage.
179;180
 Since greater glycogen accumulation has been 
reported in the diabetic myocardium of both insulin-deficient and insulin-resistant 
rodents,
206;207;341-347
 one could speculate that glycogen accumulation could be a major 
player in the perpetuation of AF by disrupting intracellular communication. However, 





Chronic hyperglycemia during diabetes accelerates the reaction between glucose and 
proteins, leading to the formation of advanced glycation end products (AGEs). AGEs 
form irreversible cross-links throughout the lifetime of many large proteins (such as 
collagen and hemoglobin), covalently modifying their structure and function, starting at 
8-12 weeks after the onset.
348
 During diabetes, and to a lesser extent during aging, AGEs 
accumulate at an accelerated rate in various cell types and produce multiple organ 
dysfunctions.
39;44
 However, the role of AGE accumulation in the development of AF in 
diabetic patients is controversial. Increased plasma levels of AGE and sRAGE (soluble 
cellular receptor of AGE) have been reported in patients with AF.
50;51
 In contrast, a recent 
large population based study reported no association between AGEs and the incidence 
and development of AF.
198
  Therefore, whether AGEs accumulation during diabetes is the 
cause of or simply correlates with the incidence of AF needs to be further investigated.   
Though diabetes has been identified as an independent risk factor for atrial 
fibrillation, the underlying pathophysiological mechanism of diabetes-induced atrial 
fibrillation remains elusive. Atrial fibrosis, AGE and glycogen accumulation have been 
suggested as biomarkers of AF; however, whether a metabolic substrate that underlies AF 
remains to be investigated. In the current study, we hypothesized that the impaired 
glucose metabolism resulting from insulin dysregulation induces an increased propensity 






MATERIALS AND METHODS 
Insulin-Deficient Animals 
Healthy and insulin-deficient (ID) diabetic FVB/N mice were used, as previously 
described.
37;295-297
 Insulin deficiency (ID) was induced at 10 – 12 weeks of age by 3 
consecutive doses of freshly prepared steptozotocin (STZ, 65-95 mg/kg IP every 48 
hours, diluted in citrate buffer), while the control group (Con) received placebo injection 
(citrate buffer). All mice were fed a standard diet to maintain body weight (10 % kcal 
from fat) for the duration of the study. Venous blood glucose concentration (facial vein) 
was measured at baseline and every week for both groups, using a glucometer (Bayer 
Contour, Tarrytown, NY) on mice fasted overnight for 8 hours. At the end of the study 
period (8 weeks), fasting serum insulin was measured using commercially available 
sandwich ELISAs (Serum Insulin ELISA kit, Millipore, MO). At 8 weeks, the mice were 
anesthetized using 3% isoflurane and euthanized by excision of the heart followed by 
either flash freezing the heart in liquid N2 or preserving in 10% formalin for 
histology/immunohistochemistry. All of the procedures of this study were approved by 
the Oklahoma State University Institutional Animal Care and Use Committee. 
Insulin-Resistant Animals 
Five-week-old C57BL/6 male mice (Charles River Laboratories) were used. After 
a one-week acclimatization period, mice were fed either a control diet (Con) (9.4% kcal 
from fat- soybean oil, 14.7% kcal protein and 75.9% kcal from carbohydrate; AIN-93M) 
or a high-fat diet (60% kcal from fat (soybean oil and lard), 20% kcal protein and 20% 
kcal from carbohydrate; Research Diets, Inc.; D12492) for 24 weeks. Both diets had 
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comparable amounts of vitamins and minerals. Body weights and blood glucose levels 
were recorded every 4 weeks throughout the experimental period. At the end of the study 
period (24 weeks), fasting serum insulin was measured using commercially available 
sandwich ELISAs (Serum Insulin ELISA kit, Millipore, MO). At 24 weeks, the mice 
were anesthetized using 3% isoflurane and euthanized by excision of the heart followed 
by either flash freezing the heart in liquid N2 or preserved in 10% formalin for 
histology/immunohistochemistry. All of the procedures of this study were approved by 
the Oklahoma State University Institutional Animal Care and Use Committee. 
Atrial Fibrillation Induction 
All of the study animals were fully electrophysiologically examined by closed chest 
transesophageal recording and atrial stimulation under anesthesia (ketamine/xylazine IP 
injection). Body surface ECG was recorded via dual subcutaneous ECG leads with 
telemetric data communication to the AliveCor iPhone application. A 2.2 Fr 6-polar 
catheter was inserted through the esophagus and positioned near the left atrium. 
Positioning of the appropriate bipolar pair of electrodes adjacent to the left atrium was 
accomplished by sequentially connecting each bipolar pair to the AliveCor application. 
Heart rate and body temperature were recorded continuously during the entire procedure 
for all of the animals. The current, in milliamperes, was determined by connecting the 
terminals of the predetermined pairs of electrodes to the battery powered (DC) stimulator 
(each pulse duration = 1 millisecond), which provided pace capture of the atrium. This 
threshold was recorded and increased by 2X to ensure constant atrial pacing at a rate 
faster than the baseline rate. By switching the same terminals to the AC-powered 
stimulator the atrial pacing threshold (in volts) was determined. This voltage threshold 
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was recorded and at 2X threshold constant atrial pacing was achieved and noted. In order 
to induce atrial fibrillation (AF), the same site was subjected to burst pacing for 10 
seconds at 2 different frequencies - 20 Hz (1200/min) and 40 Hz (2400/min) (Fig 1A) 
twice, for a total of four bursts per animal. The same protocol was applied for all 4 
groups (i.e., ID, IR groups and their aged-matched control groups).  
Duration of atrial fibrillation (in seconds), frequency (number of incidences per 
animal) (defined as an absence of a defined P-waves and presence of irregularly irregular 
R-R interval) and atrial tachycardia (increased heart rate without the defined P wave) 
were recorded after each burst pacing from the surface ECG traces. The total duration 
and frequencies of the atrial tachy-arrhythmias were recorded.  
Protein extraction  
Briefly, total protein lysates from fresh atrial tissue were collected by incubating 





Equal amounts of protein (5-20 μg) were resolved in an 8-12% SDS-
polyacrylamide gel and electrophoretically transferred (BioRad) to a polyvinyl-idine 
fluoride membrane (BioRad), as previously described.
37;294-297;299;300
 After blocking (1-
5% non-fat dry milk or 2% goat serum albumin), membranes were incubated with 
optimally diluted primary antibodies overnight (polyclonal rabbit anti-MMP9, 1:1000, 
EMD Millipore; polyclonal rabbit anti-TGFβ-1, 1:300, Abcam Antibodies) followed by a 
1 hour incubation of appropriate secondary antibodies conjugated to horseradish 
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peroxidase (polyclonal goat anti-rabbit; 1:2500, GE Healthcare NA934V). Primary 
antibodies were chosen based on their 100% sequence homology with the protein of 
interest in rodents, and validated against a positive control (i.e., tissue, peptide).  
Antibody-bound transporter proteins were quantified by enhanced chemiluminescence 
reaction (KPL) and autoradiography. Band density and molecular weight were quantified 
using GelPro Analyzer (Media Cybernetics). The data was expressed relative to 
appropriate controls. Equal protein loading was confirmed by reprobing each membrane 
with Calsequestrin monoclonal IgG (Thermo-Scientific PA1-903, 1:2500, polyclonal 
rabbit anti-dog). 
Histochemical Procedures 
Atrial tissues were fixed in 10% formalin for 24 h at room temperature. Upon 
dehydration, the tissue specimens were processed for paraffin impregnation. Five μm 
thick sections were cut and mounted on clean glass slides. These sections were processed 
for Periodic acid-Schiff (PAS) staining with (Fig 1C) and without (Fig 1B) diastase 
digestion to assess the amount of glycogen, or for Masson Trichrome staining to assess 
the amount of collagen, in accordance with standard procedures for morphologic 
analysis. Images of the stained sections were captured with Axio Vision software (Axio 
Vision 4.1 Zeiss, Germany) using a CCD camera attached to an inverted light microscope 
(Carl Zeiss, Germany). Images of all tissues were acquired at the same time with a 






















Figure 1: Periodic Acid Schiff Staining 
A) Positive control for PAS staining. Liver tissue was used to confirm PAS staining 
of glycogen (in purple) B) Glycogen Staining of the atrial tissue. Arrowheads point 
towards glycogen stores C) Diastase digestion of glycogen. Diastase digestion of 





To characterize AGE deposition in the atrial tissue, immunohistochemistry for 
carboxymethyl-Lysine was performed using automated immunostainer (Leica, Bond-III, 
Leica, Buffalo Grove, IL) on 10% formalin fixed paraffin embedded sections. The slides 
were overlaid with mouse monoclonal anti-carboxymethyl-lysine (CML-AGE) (1:100, 
Abcam, primary antibody) and normal goat serum (1:25) in PBS and incubated overnight 
at 40
0
C. This was followed by an overlay with Fluorescein isothiocyanate (FITC) 
conjugate Rat anti-Mouse IgG1 antibody (1:20, Thermo Fisher Scientific, secondary 
antibody) (Fig 2A). In order to confirm the absence of non-specific binding 10% formalin 
fixed paraffin embedded section were incubated only with Fluorescein isothiocyanate 
(FITC) conjugate Rat anti-Mouse IgG1 antibody (1:20, Thermo Fisher Scientific, 
secondary antibody) (Fig 2B). 
Olympus DP25 digital photomicroscpe was used to capture digital images of the 
CML-stained sections.  Randomly, color photomicrographs were obtained from all 
regions of atrial tissue samples (4-5 animals/group). The digital images were then 
converted to NIH Image J software and the total area of the image calculated (µm
2
) by 
setting the measurement parameters to the scale bar acquired with the image. The color 
threshold was set to identify CML-AGE only (brown stain). The images were then 
converted to black and white images in order to conduct binary measurements. To 
confirm scope intensity of CML-AGE staining, the binary images were regularly 
compared with the original image acquired using the photomicroscope. CML-AGE 
staining was reported as the area (µm
2
) in the binary image and then compared to the 















Figure 2: Carboxymethyl-Lysine-AGE staining: 
A) Atrial tissue incubated with primary and secondary antibody. CML-AGE is 
stained in brown. B) Atrial tissue incubated with only secondary antibody. The 





Number of animals: Power calculation for minimum sample size required was conducted 
using a statistical power of 0.5 and an alpha level of 0.1 to detect a 10% difference between 
groups with Sigma Stat software 3.5.  
Data Analysis: Normality and homogeneity of data were tested using Shapiro-wilk and 
Levene test, respectively. Differences between means were assessed using Student’s t-
tests, one or two-way analysis of variance (treatment and tissue) for in vitro 
measurements, as appropriate. Repeated measured 2-way ANOVA was performed for the 
in vivo measurements with Student Newman Keuls post-hoc test. If not normally 
distributed, the data was analyzed with a Mann-Whitney or Friedman test. Linear 
correlations were performed using linear regression. Statistical significance was defined 
as P<0.05. Data are presented as mean ± SE.  
RESULTS 
Validation of the insulin-deficient and insulin-resistant animal models 
In order to investigate the vulnerability of the diabetic animal to AF induction, we 
used an insulin-deficient animal model (ID) and a high-fat-diet-fed insulin-resistant 
model (IR). As expected, within 1 week after injection STZ-treated animals developed 
hyperglycemia (i.e., [glucose]>200 mg/dl), which persisted throughout the experimental 
period. The paired control group remained euglycemic (Fig 3A). There was no difference 
in body weight between groups (Fig 3B). The STZ-treated animals were hypoinsulinemic 
at the end of 8 weeks (Fig 3C).  
112 
 
Within 2 weeks the blood glucose levels of the high-fat-diet fed animals started to 
elevate and mild fasting hyperglycemia was maintained until the end of the 24 week 
study period. The blood glucose concentration of the high-fat group was significantly 
higher than that of the euglycemic control group (Fig 3D). Which was also significantly 
higher compared to the control animals until the end of the 24 week study period. These 
animals also quickly became obese with approximately 2.5 times their initial body weight 
and were significantly higher compared to the control group at the end of the study period 
(Fig 3E). The fasted serum insulin level of the high-fat diet animals were significantly 
higher at the end of 24 weeks compared to the paired control animals confirming 










































Figure 3: Validation of the insulin-deficient and insulin-resistant animal models 
Validation of the insulin-deficient (ID) diabetic animal model.  A) Mean ± SE venous 
blood glucose concentration obtained at baseline and up to 8 weeks in STZ-treated (ID) and 
age-matched control (Con) mice (n=8-9/group). B) Mean ± SE body weight obtained at 
baseline and up to 8 weeks in STZ-treated (ID) and age-matched control (Con) mice (n=8-
9/group). C) Mean ± SE serum insulin concentration obtained at 8weeks from STZ-treated 
(ID) and age-matched control (Con) mice (n=4-6/group).Validation of the insulin-resistant 
(IR) animal model.  D) Mean ± SE venous blood glucose concentration obtained at baseline 
and up to 24 weeks in high-fat-diet-fed (IR) and age-matched control (Con) mice (n=20/group). 
E) Mean ± SE body weight obtained at baseline and up to 24 weeks in high-fat-diet-fed (IR) 
and age-matched control (Con) mice (n=20/group). F) Mean ± SE serum insulin 
concentration obtained at 24 weeks from high-fat-diet-fed (IR) and age-matched control (Con) 
mice (n=20/group). ID: Insulin-deficient; IR: Insulin-resistant; Con: control animals paired with 




Vulnerability of the insulin-deficient and insulin-resistant animals to atrial 
fibrillation induction 
In order to investigate the vulnerability of our animal models to the induction of 
AF, the atria of the healthy, insulin-deficient (ID) and insulin-resistant (IR) animals were 
paced with a total of 4 consecutive 10 second bursts of 20Hz (1200/min) (2 bursts) and 
40Hz (2400/min) (2 bursts). Our results indicated longer duration and greater frequency 
of atrial arrhythmia in insulin-deficient and insulin-resistant animals (P<0.05, Fig 2A-D). 
We first quantified the duration (Fig 4A/C) and frequency (Fig 4B/D) of all observed 
atrial tachy-arrhythmias, including atrial fibrillation, atrial tachycardia and sick sinus 
syndrome in both ID and IR animals. Our results indicated a 6 and 8 times greater 
average duration of arrhythmia in the ID and IR, respectively, compared to their paired 
control groups. Similarly, the ID and IR animals displayed 4 and 6 times greater 
frequency of atrial tachy-arrhythmia compared to the healthy controls. In addition, 85% 
of the ID (6 out of 7) and 100% of the IR (7 out of 7) subjects were susceptible to some 
or all forms of atrial tachy-arrhythmia. Next, we specifically quantified the duration and 
frequency of atrial fibrillation in the ID and IR animals. Our results indicated 
significantly greater frequency of AF in both ID (P<0.05, Fig 4F) and IR (P<0.05, Fig 
4H) animals compared to their age-matched control groups. These findings strongly 
































Figure 4:  Vulnerability of the insulin-deficient and insulin-resistant animals to atrial 
fibrillation induction 
 (A) Longer duration and (B) greater frequency of combined atrial arrhythmia in the 
insulin deficient (ID) animals (n=4-7 mice/group); # P<0.05 vs. Con; (C) Longer duration 
and (D) greater frequency of combined atrial arrhythmia in the insulin resistant (IR) 
animals (n=4-7 mice/group); # P<0.05 vs. Con; (E) Longer duration and (F) greater 
frequency of atrial fibrillation in the ID animals (n=4-7 mice/group); # P<0.05 vs. Con. 
(G) Longer duration and (H) greater frequency of atrial fibrillation in the IR animals 
(n=4-7 mice/group); # P<0.05 vs. Con. Atrial arrhythmia: Includes atrial fibrillation, atrial 
tachycardia and sick sinus syndrome. Frequency: Average of the total incidence of atrial 
arrhythmia/atrial fibrillation. ID: Insulin-deficient; IR: Insulin-resistant; Con: control animals 





Glycogen accumulation in the atria of insulin-deficient and insulin-resistant subjects 
In order to investigate alterations in atrial metabolism, we used Periodic acid-
Schiff (PAS) staining to measure potential glycogen accumulation (Fig 5 A-H) in the 
insulin-deficient (ID) and insulin-resistant (IR) atria. In both control groups, the presence 
of glycogen was minimal in both the right and left atria (Fig 5). Furthermore, we did not 
identify any differences in glycogen accumulation between the diseased groups vs. paired 
control or the right vs left atria. Due to the low intensity of glycogen staining, 












































Figure 5: Glycogen accumulation in the atria of insulin-deficient and insulin-
resistant subjects 
Representative images demonstrating no alteration of glycogen deposition in the 
control (Con), insulin-deficient (ID) and insulin-resistant (IR) atria. n=5/group; 
Methods: Periodic-acid Schiff (PAS) Stain (Purple). Scale Bar: 200µm. ID: Insulin-




Accumulation of advanced glycation end product in the atria of insulin-deficient 
and insulin-resistant mice 
Immunohistochemistry was used to measure the deposition of AGEs in atria of 
the control, insulin-deficient (ID) and insulin-resistant (IR) mice. AGE deposition was 
compared between the control vs diseased groups, as well as the right vs left atria. 
Quantification of positive staining for carboxymethyl lysine, a major AGE (in brown) 
indicated that there was no difference of AGE deposition in the atria of ID and IR groups 






































Figure 6 : Accumulation of advanced glycation end products in the atria of insulin-
deficient and insulin-resistant mice 
 No alteration in CML-AGE deposition in the Control, insulin-deficient (ID) and 
insulin-resistant  (IR) atria.  A/B) Representative IHC images of the Con and ID right atria. 
C) Mean ± SEM of  CML-AGE deposition in the Con vs ID right atria; n=5-6/group; D/E) 
Representative IHC images of the Con and ID left atria. F) Mean ± SEM of CML-AGE 
deposition in the Con vs ID left atria; n=5-6/group.  G/H) Representative IHC images of the 
Con and IR right atria. I) Mean ± SEM of  CML-AGE deposition in the Con vs IR right atria; 
n=2-4/group; J/K) Representative IHC images of the Con and IR left atria. L) Mean ± SEM 
of CML-AGE deposition in the Con vs IR left atria; n=3-4/group. Methods: 
Immunohistochemistry; Anti Carboxymethyl Lysine (Brown); Scale Bar: 500µm. ID: Insulin-
deficient; IR: Insulin-resistant; Con: control animals paired with age matched ID or IR 




Atrial fibrosis in the insulin-deficient and insulin-resistant atria 
Since atrial fibrosis and atrial remodeling has been established as a pre-cursor to 
AF,
130;135;155;160;162
 we determined whether atrial fibrosis was present in the atria of ID 
and IR animals. We first quantified the protein expression of the pro- (latent) and active- 
(active form of the protein; activation is achieved from proteolytic cleavage of the latent 
form followed by dimerization)
349
 TGFβ-1, a pro-fibrotic marker by Western blotting. 
Our results demonstrated a significant increase in the expression of the active TGFβ-1 in 
the atria of both ID (P<0.05, Fig 7A) and IR (P<0.05, Fig 7B) subjects compared to their 
respective healthy controls.  We also quantified the protein expression of MMP-9, which 
has been identified as an independent risk factor for AF and an activator of TGFβ-
1.
145;162;350
 Our results indicated up-regulation of active-MMP-9 in the ID (P<0.05, Fig 
7C) and IR (P<0.05, Fig 7D) atria. These findings suggested that the atria of the animals 
with insulin dysregulation are susceptible to fibrosis. We then performed Masson 
Trichrome Staining to assess the presence of (Fig 8) of atrial fibrosis in the healthy and 
diseased animals. Similar to the control groups, we did not observe any fibrotic deposits 
in the atria of the ID or IR group. Therefore, these findings are indicative of the fact that 
at this stage the ID and IR subjects, although vulnerable to AF induction, do not 
































Figure 7: Increased expression of fibrotic markers in the atria of the insulin-
deficient and insulin-resistant animals  
Increased protein expression of Active Transforming Growth Factor β-1 (TGFβ-1) 
in A) ID atria and B) IR atria. n=5/group; (#, P<0.05 vs Con); Increased protein 
expression of Active Matrix Metallo-Proteinase-9 (MMP-9) in C) ID atria and D) IR 
atria. n=5/group; (#, P<0.05 vs Con); Values normalized to respective controls; 
Methods: Western blotting. ID: Insulin-deficient; IR: Insulin-resistant; Con: control animals 


























Figure 8: Atrial fibrosis in the atria of the insulin-deficient and insulin-
resistant animals 
Representative images demonstrating the absence of fibrotic deposits in the 
Control (Con), insulin-deficient (ID) and insulin-resistant (IR) atria. n=4-
5/group; Methods: Masson Trichrome Stain (Blue staining collagen). Scale Bar: 
500µm; ID: Insulin-deficient; IR: Insulin-resistant; Con: control animals paired with 





The goal of this study was to investigate the possible underlying substrates that render the 
diabetic atria vulnerable to AF induction. Our results indicated that 1) both the insulin-
deficient and insulin-resistant mice have increased vulnerability and propensity to AF 
induction; 2) there was no significant accumulation of glycogen, AGE or fibrotic deposits 
in the atria of subjects with insulin dysregulation. 
Recent epidemiologic studies have identified diabetes as an independent risk 
factor for AF.
15;17;19;185;189-192
 A large population-based study reported that 7.6% of the 
diabetic subjects displayed baseline AF.
186
 It has also been suggested that combination of 
insulin-resistance, and fluctuations in the glycemic state is one of the mechanisms of diabetes-
induced AF.
19
 In a similar study, it was reported that high fasting blood glucose and 
insulin levels were correlated with the risk factor for the development of AF in the 
diabetic patients.
15;184
 The risk factor of AF is also suggested to increase with the duration 
of diabetes and level of glycemic control.
15
 Additionally, AF attacks in insulin-dependent 
type 1 diabetic patients have been associated with periods of hypoglycemia.
187;188
 
Another study by Rigalleau et al. reported that major hyperglycemic episodes precede AF 
attack in insulin-resistant type 2 diabetes patient.
16
 Together, the results of these studies 
suggest a strong correlation of insulin disturbance and an inadequate glycemic control 
with AF.
15;17;19;185;189-192
 In agreement with the above studies
15;17;19;185;189-192
 our findings 




In the absence of a spontaneous model of AF, it has been difficult to investigate the 
pathophysiological link between diabetes and AF. Therefore, in order to investigate the 
mechanisms of AF development and to emulate the pathological conditions during AF, 
transvenous or transesophageal rapid atrial pacing has been used. 
154;334-337
  In the current study 
we have used transesophageal atrial pacing, which is minimally invasive, does not require 
mechanical alterations of the atrial tissue (invasive open chest stimulation or catheterization) 
and allows the animal an immediate recovery.  The results from the transesophageal atrial 
pacing of the insulin-deficient (ID) animals indicated that the ID mice had greater frequency 
and longer duration of atrial tachy-arrhythmias, including atrial fibrillation and atrial 
tachycardia. Eighty five percent of the ID animals displayed some or all forms of tachy-
arrhythmias. Similarly, IR mice had greater frequency and longer duration of atrial tachy-
arrhythmia. The IR group demonstrated 100% vulnerability to AF induction whereas only 50% 
in the control animals displayed mild AF. The overall duration of AF was approximately 6 
times longer in both of the groups with insulin dysregulation compared to their respective 
controls. Together, these data strongly suggest that insulin dysregulation significantly increases 
the arrhythmogenicity of the atria. 
We further investigated the possible underlying mechanisms underlying increased 
arrhythmogenicity of the atria. One of the predominant changes that have been reported in 
the atria at the onset of AF is glycogen accumulation.
176-180
 Increased glycogen 
accumulation in the left atrial appendage has been reported at the onset of AF in large 
animal models, where persistent AF was induced by atrial pacing in healthy goats.
179;180
 
These studies reported that glycogen accumulated at the intercalated discs and at the 
myocyte junctions, inducing lateral and longitudinal conduction blockage in the electrical 
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signal transduction pathway. This phenomenon facilitated the formation of the re-entry 
circuits and thereby promoted AF induction.
179;180
  In similar studies, Ausma et al. 
reported that there was significant electrical (shortening of the atrial refractory period) 
and structural remodeling (including glycogen accumulation, loss of contractile apparatus 
function and two fold increase in myocyte cell size) that occurred due to the induction of 
AF by rapid atrial pacing in healthy goat hearts. 
176;177;181
 In contrast to these studies, 
Kondrat’ve et al. reported that AF induction in healthy Wistar rats (5-10 mins for 8-10 
times) depleted the atrial glycogen storage by activating the glycogen phosphorylase 
system. They speculated that this was caused by the increase in need of energy 
consumption for the inefficient and frequent contractions of the fibrillating 
myocardium.
219
 However, the animal models used in these studies were healthy at the 
beginning of the study and not diabetic.
176-181
 We recently reported impairment in regulation 
of the insulin-sensitive glucose transporter isoforms GLUT4 and GLUT8 in the atria of ID and 
the IR subjects (using the same animal models as the current study). In light of these recent 
findings, we investigated potential alterations in glycogen accumulation in the atria of ID and 
IR mice. In contrast with previous studies that reported increased glycogen accumulation 
in the myocardium of diabetic patients and rodents,206;207;341-347 our results did not indicate 
any distinct location or distribution of glycogen in the ID or the IR groups compared to 
their respective controls. Possible interpretations of these findings include the fact that: 1) 
the mouse atria, being extremely small in size, do not possess the capacity for glycogen 
accumulation; 2) due to the extremely high baseline heart rate, the mouse atria utilize 
most of the glycogen stores under physiological conditions (AF and glycogen 
accumulation are reported in large animal models).  
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Advanced glycation end products (AGEs) are formed during chronic 
hyperglycemia by a glycosylation reaction (Millard’s reaction) between the large proteins 
with slow turnover rate and the glucose present in the blood. AGEs, once formed, are 
irreversible and have been deemed responsible for many of the cardiac complications 
associated with diabetes.  The role of AGEs in the perpetuation and progression of AF 
have been debated in recent studies. In a study conducted by Begieneman et al., increased 
expression of major AGEs (N
ɛ
- carboxymethyl lysine) was reported in the left atrial 
appendage of AF patients.
50
 Raposeiras-Roubin et al. reported increased levels of plasma 
AGEs and sRAGE (soluble receptor for AGE) in patients with AF.
51
  In contrast, 
Schneider et al. reported that, in a large community based study, the incidence of AF was 
unrelated to the level of sRAGE. 
198
 Therefore, whether AGEs play a direct role in the 
development of AF remains elusive.  In the current study, our results do not indicate any 
difference in AGE deposition between the highly vulnerable (to AF) ID and IR atria and 
the less susceptible control atria.   Therefore, in the current study our findings do not 
demonstrate any association between AGE deposition and AF during insulin 
dysregulation. 
The relationship between atrial fibrosis and AF has been the subject of intense 
investigations in the past 25 years. Atrial fibrosis is difficult to reverse and therefore has 
been considered as major contributor in the progression from paroxysmal to persistent 
and eventually, permanent AF.
157
 It has been suggested that fibrotic deposits in the atria 
can cause conduction blockage and thereby create a disorganized conduction wave, 
facilitating the development of AF. Interestingly, it has been reported that the atrium is 
more vulnerable to fibrosis compared to the ventricle.
159
 Venteclef et al. reported 
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increased atrial fibrosis constituting collagen I, III and VI in the atrial biopsies of human 
AF patients.
164
  In another study, Frustaci et al. reported the existence of patchy fibrosis 
in endo-myocardial biopsies from the right atrium of human patients with paroxysmal 
lone AF (AF in the absence of other cardiac complications).
36;60
 In a diabetic small 
animal model, Kato et al. reported fibrotic deposits in the atria that demonstrated 
increased atrial arrhythmogenicity.14 Therefore, in the current study we investigated atrial 
fibrosis in the ID and IR animals, which demonstrate high susceptibility to AF.. To this 
end, we measured pro-fibrotic marker TGFβ-1, MMP-9 and collagen deposition in the 
atrial tissue.  
Transforming growth factor 1 (TGFβ-1), secreted by both myocytes and 
fibroblasts, is one of the well-established pro-fibrotic molecules. It has been suggested 
that cardiac overexpression of active TGFβ-1 causes atrial fibrosis, disruption in atrial 
conductivity, and promotes AF.
162;163
 Verheule et al. reported that selective 
overexpression of TGFβ-1 in the atrium was sufficient to increase AF inducibility during 
rapid atrial pacing in a transgenic mouse model.
162
 In a large animal model, Polejaeva et 
al. reported that overexpression of TGFβ-1 in the heart resulted in atrial fibrosis which in 
turn increased inducibility of AF in transgenic goats.
165
 Together, the results from these 
studies indicate a strong connection between enhanced TGFβ-1 and AF propensity. In 
agreement with these findings, our results demonstrate significantly higher expression of 
active TGFβ-1 in both ID and IR atria compared to control, suggesting a significant 
association between overexpression of TGFβ-1 and AF.  
Recently, increased expression of MMP-9 has been identified as an independent 
risk factor of AF as it contributes to atrial structural remodeling and dilation.
145
  MMPs 
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(Matrix Metalloproteinases), responsible for the degradation of ECM proteins, are 
expressed at a very low level in the healthy myocardium. However, substantial 
upregulation of MMPs have been associated with heart failure and AF.
171
  In a case-
cohort-based study, Huxley et al. reported that increased MMP-9 was associated with an 
increase in risk for AF.
175
 Nakano et al. also reported significant increase in MMP-9 
levels in atrial biopsies of human patients with both paroxysmal and persistent AF.
145
 A 
progressive increase of the MMP-9 level was reported with the severity of the disease 
(from paroxysmal to persistent AF). In animal models of AF, Chen et al. reported that 
during rapid atrial pacing in a porcine model, there was an increased expression and 
activity of MMP-9   in its active form.
166
 In a similar study Hoit et al. reported that in 
rapid atrial pacing canine model there was increased MMP-9 activity in the atrium.
173
 In 
addition, it has been postulated that MMP-9 modulates the activation of TGFβ-1 and 
thereby contributes to atrial fibrosis. Therefore, the results of these studies indicated that 
MMP-9 significantly contributes towards atrial remodeling and render the atria 
susceptible to AF. In the present study, our results demonstrated a significant up-
regulation of active MMP-9 in the ID and IR atria in confirmation with the suggested link 
between up-regulation of MMP-9 during AF. Overall, the overexpression of TGFβ-1 and 
MMP-9 suggested that the ID and IR animals have increased vulnerability towards atrial 
fibrosis, which could be one of the reasons that these animals are highly susceptible to 
AF. However, when we investigated for atrial fibrosis itself, no fibrotic deposits were to 
be found in either of the diseased atria, suggesting that there are alternate mechanisms 





Using transesophageal atrial pacing, we demonstrated that both the insulin-
deficient and insulin-resistant mice have greater vulnerability and propensity to atrial 
fibrillation induction. Although we previously reported alterations in atrial glucose 
transport, we did not report any atrial fibrosis, glycogen or AGE accumulation in the atria 
of the subjects with insulin dysregulation in the current study. Therefore, the findings 
from this study indicate that insulin dysregulation, resulting in impaired glucose uptake, 
is sufficient to provide a metabolic arrhythmogenic substrate and could be an early 
pathogenic factor of AF.  
 








The goal of this study was to investigate the mechanisms underlying diabetes-
induced atrial fibrillation. To this end, the regulation of insulin sensitive glucose 
transporter 4 and 8 in the healthy and diabetic atria (type 1 and type 2) were investigated. 
In addition, the vulnerability of the diabetic subject to atrial fibrillation was tested. The 
findings from this study  indicate that, 1) The major cardiac isoform GLUT4 and novel 
isoform GLUT8 are insulin sensitive in the healthy atria and are regulated by the 
downstream insulin signaling pathway, 2) The expression and regulation of the insulin 
sensitive GLUTs in the atria are downregulated during insulin-deficient type-1 diabetes 
and insulin resistance, 3) Both insulin deficiency and insulin resistance significantly 
increase the vulnerability and propensity to atrial fibrillation induction, and 4) The 
animals with insulin dysregulation do not demonstrate a fibrotic atria along with 
unaltered glycogen and AGE accumulation compared to the healthy animals. 
Collectively, our data suggest that in the absence of structural remodeling and atrial 
fibrosis, disturbances in the insulin and glycemic states were sufficient to increase the 
susceptibility towards AF. This finding is in agreement with our central hypothesis that,                                                                                                  
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“Dysregulation of glucose metabolism in the diabetic atria is underlying the diabetes-
induced development of AF.” 
The heart utilizes glucose as a major energy substrate as it generates ~30 % of its 
total energy (ATP) from glucose oxidation during physiological condition.
21
 Therefore, 
cardiac glucose uptake and utilization is crucial for proper cardiac function. This is 
crucial to the fact that the atria, which contains the pacemaker of the heart, significantly 
contributes to the overall cardiac function.  During glucose oxidation 38 molecules of 
ATP are generated from each molecule of glucose. It can be suggested that reduced 
glucose uptake due to the dysregulation of major cardiac GLUT isoforms (GLUT4 and 
GLUT8) would lead to an overall reduction in ATP generation during the absorptive 
state. Decline in ATP generation in turn could potentially cause abnormality in the 
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 ATPase and the SERCA pumps are responsible for the clearance and 
recycling of intracellular Ca
2+
 during diastole. However, impaired SERCA function (due 
to the lack of available ATP) could lead to alteration in Ca
2+
 handling and eventually 
cytosolic Ca
2+
 overload. Intracellular Ca
2+
 overload is responsible for 1) the prolongation 
of the action potential duration (APD);
130;135
 2) the formation of delayed and early 
afterdepolarization (DAD and EAD respectively);
358;360;361
 3) sarcoplasmic reticulum 
spontaneous Ca
2+
 release during diastole;
358;362
 and 4) mitochondrial Ca
2+
 overload, all of 
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which are arrhythmogenic (directly or indirectly). Prolongation of the APD allows the 
formation of delayed afterdepolarizations (DADs) during the relative refractory period 
and subsequently allows the formation of early afterdepolarizations (EADs). EADs and 
DADs that are large enough to reach the threshold potential of the atrial myocyte can 
initiate ectopic firing.
358;359;363
 It has been reported that repetitive DAD formation can 
cause atrial tachycardia.
363
 In addition, increased EAD formation has been observed in 
AF patients and during atrial pacing in large animal models.
360;364
 During intracellular 
Ca
2+
  overload the mitochondria itself accumulate a significant amount of Ca
2+
 via the 
Ca
2+




 overload initiates increase in the 
production of reactive oxygen species (ROS) and free radicals, which are detrimental to 
the mitochondria itself and cause damage to the mitochondrial DNA.
367
 This results in 
increased intracellular ROS and oxidative stress. Mitochondrial damage and enhanced 
oxidative stress have been significantly associated with AF.
367-369
 Figure 1 depicts the 
proposed mechanisms by which alteration in GLUT trafficking/glucose uptake could lead 
to the development and maintenance of AF.  
Overall, the results obtained from this study indicate that insulin dysregulation, 
resulting in impaired glucose uptake, is sufficient to provide a metabolic arrhythmogenic 
substrate and could be an early pathogenic factor of AF. Therefore, better understanding 
of the regulation of glucose transport may lead to the discovery of novel therapeutic 
targets for the treatment of cardiovascular complications associated with diabetes, 



















Figure 1: Schematic diagram depicting the proposed role of impaired 
glucose uptake in the initiation of atrial fibrillation. ATP: Adenosine tri 
phosphate; APD: Action potential duration; ROS: Reactive oxygen species; 
SERCA: Sarcoplasmic calcium ATPase pump; Ca
2+
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AF  Atrial Fibrillation 
AGE  Advanced Glycation End Products 
AKT  Protein Kinase B; Serine/Threonine Specific Protein Kinase 
AMPK  AMP (5’ Adenosine Mono Phosphate) Activated Protein Kinase  
APD  Action Potential Duration  
AS160  Akt Substrate of 160kDa 
ATP  Adenosine Tri-Phosphate 
CAMK Calcium/Calmodulin dependent Protein Kinase 
CVD  Cardio Vascular Disease 
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DADs  Delayed After Depolarization 
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ER  Endoplasmic Reticulum 
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GADAs Glutamic Acid Decarboxylase 
GAP  GTPase Activating Protein 
GLUT  Glucose Transporter 
HLA  Human Leukocyte Antigen  
IA2A  Tyrosine Phosphatase 
ID  Insulin-deficient 
IL-1β  Interlukin-1 beta  
IR  Insulin-resistant 
IRS-1  Insulin Receptor Substrate-1 
LAA  Left Atrial Appendage 
MHC  Major Histocompatibility Complex 
MMP  Matrix Metalloproteinase 
mRNA  Messenger RNA 
mTORC2 Mammalian Target of Rapamycin Complex 2 
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NFκB  Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells 
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PAS  Phospho Akt Substrate 
PFK-1  Phospho Fructo Kinase-1 
PI3-K  Phosphoinositide 3-Kinase 
PDK-1  Phosphoinositide Dependent Kinase-1   
PIP2  Phosphatidylinositol 4,5-bisphosphate 
PIP3  Phosphatidylinositol (3,4,5)-trisphosphate 
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RAGE  Receptor for Advanced Glycation End products 
RNA  Ribonucleic Acid 
RTK  Tyrosine Kinase Receptor Family 
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SMAD  Mothers Against Decapentaplegic Homolog 
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STZ  Streptozotocin 
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TCA  Tricarboxylic Acid  
TGFβ-1 Transforming Growth Factor beta 1 
TGN  Trans Golgi Network 
TIMP  Tissue Inhibitor of Matrix Metalloproteinase 
TNF-α  Tumor Necrosis Factor Alpha, TNFα 
SERCA Sarcoplasmic Reticulum Calcium ATPase Pump 
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